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CHAPTER 1. GENERAL INTRODUCTION 
Thesis Organization 
This thesis describes a genotypic and phenotypic characterization of the equine 
infectious anemia virus (EIAV) surface unit envelope glycoprotein (SU). The genetic 
component emphasizes our findings of SU variants present during the inapparent stage of 
disease. In particular, we characterize differences in the viral quasispecies present during the 
acute, chronic, and inapparent stages of disease. The phenotypic component identifies 
differences in replication and neutralization phenotypes for representative variants at each 
stage of disease. The dissertation is in manuscript format, consistent with American Society 
for Microbiology journals, and is divided into four chapters, two of which are presented as 
journal articles. Chapter 1 is a general introduction to mechanisms of virus persistence, with 
an emphasis on lenti viruses. It includes a general background of the disease caused by EIAV 
and introduces important aspects of the virus as a model of lenti viral persistence. The 
introduction provides sufficient information to enable the reader to understand the scope and 
significance of the research. Chapter 2 describes the discovery of different populations of 
viral variants at different stages of disease recovered from an experimentally infected pony. 
Two data sets of viral variants from within the SU were compiled by me with analyses 
contributed by Wendy Wood and Robert Thompson. The experimental infection, collection 
of serum samples, and recording of the pony's clinical profile were performed by our 
collaborator, J. Lindsay Oaks. This chapter will be submitted for publication in the Journal of 
General Virology and represents the initial work required for advances presented in Chapter 
3. The latter details identification of the major variants representative of the different stages 
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of disease that were then used to establish chimeric viruses for biological characterization. 
Yuxing Li helped design the cloning strategy, Amanda Johnson helped prepare cloning 
vectors, and Yvonne Wannemuehler contributed with development of virus stocks. The data 
in this chapter identify variation in the SU that contributes to viral phenotypes resistant to 
neutralization by broadly acting, cross neutralizing antibody and that may have decreased 
replication fitness in vitro. Following Chapter 3 is a general conclusion of these studies, their 
implication for studies of EIAV and lenti viruses in general, and future steps that may be 
taken based upon insights gained from the presented work. 
Introduction to Strategies of Virus Persistence 
In 1954, Sigurdsson's observations of sheep experimentally infected with Maedi-
Visna virus, a lenti virus of sheep, led him to propose the concept of virus persistence (64,88). 
The realization that there may be a lengthy incubation period before the detection of clinical 
disease suggested that certain viruses could persist without immediate ill effect to the host. 
Support for this concept came from studies of the histopathology associated with viruses 
eliciting an acute response compared with viruses which persisted. Acute disease was 
typically characterized by tissue destruction, cell necrosis, and lymphoid infiltration, whereas 
the expanding number of identified viruses that persisted in the host failed to cause lymphoid 
infiltration and cell necrosis. In general, viruses that persisted were usually cell-associated, 
minimally expressed surface glycoprotein, and elicited and evaded both humoral and cellular 
immune responses. It also became clear that viruses that persist generally employ a strategy 
of viral replication that ensures a nonlytic phenotype, and that the immune response was 
ineffective in recognizing and clearing virus and/or virus-infected cells (64). Thus, clinical, 
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histopathologic»!, immunologic, and in vitro studies of virus replication suggested that some 
viruses are capable of persisting within the host. It is now well recognized that three general 
conditions contribute to persistence of virus. The virus is typically non-cytopathic, able to 
maintain its genome in host cells for an extended period, and able to avoid detection and 
elimination by the host. 
Employing a strategy of replication that minimizes lysis of the host cell is essential 
for persistence. The cell type often is the determining factor for many viruses in whether or 
not infection will result in cytolysis. As a result, mechanisms that inhibit cytolysis are often 
directly linked to maintenance of the viral genome, which may be mediated by several 
mechanisms. For lenti viruses, integration of the genome in the host's chromosomes assures 
propagation of the genome by the cell. In addition, RNA viruses, such as lenti viruses, 
typically maintain chronic, low levels of virus replication. On the other hand, DNA viruses 
more effectively establish latency because the host cell performs processes that help maintain 
the genome in a quiescent state. For example, Epstein-Barr Virus infection of B lymphocytes 
involves infection of a nonpermissive cell (64). As a result, expression of genes is very low. 
In order to avoid detection by immunologic surveillance, many RNA and DNA 
viruses which persist have developed means of limiting expression of viral and cellular 
proteins on infected cells that are important for activation of an immune response. Examples 
include mechanisms to decrease viral protein expression, alteration of expression of 
lymphocyte adhesion molecules, and alteration of MHC expression. Many RNA and DNA 
viruses have developed strategies that interfere with antigen processing and presentation. The 
E3 gene product of adenovirus type 2 complexes with MHC antigens and prevents the MHC 
from being correctly processed in the cell. E3 does this by inhibiting terminal glycosylation 
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of the MHC antigens. As a result, there is reduced MHC class I expression on the surface of 
the infected cell. Among the primate Antiviruses, the nef gene product interferes with MHC 
class I expression on the cell surface (39,92). Thus, interference with processing and 
presentation of viral antigen is a viral strategy common to viruses that persist within the host. 
Viruses may also reduce lymphocyte or macrophage function, integral components of 
immunity- This may be accomplished by (I) inducing cytokine production which in turn may 
alter transcription of host genes, (2) directly mimicking cytokine activity, and (3) host cell 
interference, leading to generalized immunosuppression. Another strategy of immune 
evasion involves cell tropism. For example, neurotropic viruses infect neurons, cells which 
lack MHC expression (64). Many of these viruses also generate genetic variants and/or 
diminish expression of viral genes or their products during the replication cycle, further 
thwarting immune detection. Lenti viruses employ many of these strategies and produce 
lifelong infection in the host. 
The human immunodeficiency virus (HIV) pandemic is the most devastating in 
recorded history, killing 40 million people in the last 20 years. The World Health 
Organization estimates that as of December 2002 there are 42 million people living with 
HIV/AIDS. Sub-Saharan Africa accounts for 29,400,000 adults and children with HIV/AIDS 
(95). Projected estimates indicate that up to 100 million new infections will occur in the next 
decade (58). Despite billions of dollars spent in research, an effective vaccine has yet to be 
developed. Fortunately, however, basic research has lead to development of drugs that target 
critical steps in the virus life cycle that effectively reduce virus load. The highly active 
antiretroviral therapy (HAART) protocol generally entails administration of a combination of 
nucleoside and nonnucleoside reverse transcriptase inhibitors in combination with one or 
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more protease inhibitors (91). This drug regimen can permit restoration and maintenance of a 
CD4+ T helper cell population, forestalling progression to AIDS. Unfortunately, the drugs 
can have toxic side effects that often require temporary discontinuation. Moreover, cost can 
be a limiting factor, particularly for those lacking insurance and the millions living in 
developing countries. Detection of drug resistant virus and sanctuary sites suggest that a 
patient's life may be prolonged, but not indefinitely. Thus, there is a dire need to better 
understand the mechanisms of persistence that HIV, and Antiviruses in general, employ that 
thwart immunologic and pharmaceutical control. Perhaps studies that focus on the basic 
mechanisms of virus persistence will lead to development of an effective vaccine for HIV 
and other Antiviruses. 
Overview of Lentiviruses 
Lenti viruses are single-stranded RNA viruses associated with chronic diseases of the 
immune system and central nervous system (92). In addition to gag, pol, and env, found in all 
retroviruses, lentiviruses contain genes that enhance virus replication and persistence. 
Lenti viral replication inherently promotes persistence, particularly through the production of 
genetic and antigenic variants, integration within the host's chromosomes, and regulation of 
viral gene expression. The replication cycle of HIV is the best characterized among the 
lentiviruses. 
Virion binding to the host cell 
HIV productively infects cells after virion binding to the cell membrane. The trimeric 
surface envelope glycoprotein (SU) engages CD4 on the target cell and induces 
conformational changes within SU that allow binding to a chemolane receptor. In vivo 
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infection usually involves either CCR5, which binds macrophage-tropic virus, or CXCR4, 
which binds T-cell tropic virus. CCR5 (R5) virus mediates mucosal and intravenous routes of 
infection whereas CXCR4 (X4) virus is generally found with CD4+ T cell depletion and 
progression to AIDS. The chemokine receptors localize to lipid rafts, a suitable environment 
for membrane fusion (32). 
HFV SU also binds the C-type lectin, DC-SIGN, found on dendritic cells, with high 
affinity (32). Virions bound to DC-SIGN are internalized into an acidic compartment which 
likely prepares the virion for fusion. From the acidic compartment, the virion is displayed on 
the dendritic cell's surface. Mature dendritic cells migrate to the lymph node to engage T 
cells whereupon virus bound to the dendritic cell can bind T cells. 
Fusion 
Once the viral SU has engaged CD4 and a chemokine receptor, the coiled-coil 
transmembrane protein (TM) conformational^ changes to project three peptide fusion 
domains into the lipid bilayer of the target cell. Fusion of the virion and cell membranes 
occurs via TM hairpin formation which brings the virion and cell membranes into apposition. 
Release of HIV viral cores into the cytosol occurs with fusion (32). 
Uncoating and reverse transcription 
Inside the cell, phosphorylation of matrix (MA) by mitogen activated protein kinase 
leads to uncoating of the viral core and generation of the viral reverse transcription complex. 
This complex is composed of two genomic RNAs, tRNALy$ primer, reverse transcriptase 
(RT), integrase (IN), MA, nucleocapsid (NC), viral protein R (Vpr), and host proteins. 
Reverse transcription results in conversion of the RNA genome to a DNA intermediate. The 
new complex, the preintegration complex (PIC), is composed of double stranded viral cDNA, 
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IN, MA, Vpr, RT, and the high mobility group DNA-binding protein [HMGI(Y)J. The PIC 
moves toward the nucleus via microtubules and enters the nucleus through the nuclear pore. 
Nuclear targeting signals are contained on MA, Vpr, and IN. 
Integration 
Once inside the nucleus, a functional pro virus is produced provided a cooperative 
interaction of host proteins HMGI(Y) and barrier to autointegration factor (BAF) and IN 
occurs. IN cleaves the pro viral DNA at either end and catalyzes a joining reaction that inserts 
the pro viral DNA into the host chromosome. Most infected cells contain more than one 
provirus (32). 
Transcription 
An integrated provirus contains a transcriptional unit in its 5' long terminal repeat 
(LTR) which functions similar to eukaryotic transcriptional units. It contains upstream and 
downstream promoter elements which help position RNA polymerase II at the site of 
initiation of transcription. The transcriptional enhancer located upstream of the promoter 
binds nuclear factor te B (NF K B), which increases the efficiency of transcriptional initiation. 
The viral protein Tat is involved in a marked increase in viral gene expression. Tat binds the 
transactivation response element (TAR), a viral RNA stem loop. Together with cyclin Tl, 
Tat bound to TAR recruits cyclin-dependent kinase 9, which phosphorylates the C-terminal 
domain of RNAPIL This event mediates transition from initiation to elongation (32). 
Nuclear export of viral transcripts and translation 
Following transcription of the viral genome, spliced and incompletely spliced 
products are exported to the cytoplasm. The incompletely spliced transcripts encodê the 
structural, enzymatic, accessory proteins, and serve as genomic RNA required for virion 
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assembly. The balance of spliced and incompletely spliced transcripts is partially determined 
by expression of Rev protein, which binds the RNA stem loop called the Rev response 
element (RRE) located in the env gene. Binding and multimerization of Rev on the RRE 
result in nuclear export of the incompletely spliced RNA via the CRM 1 /exportin-1 pathway. 
Translation of viral messages occurs in the cytoplasm. 
Budding 
Assembly of virion components occurs at the plasma membrane. Gag-Pol, Gag 
polyproteins, Env, Vpr, and two genomic RNAs all play a role in assembly. Gag polyproteins 
form the viral capsid. Gag polyprotein is palmitoylated and myristoylated, resulting in 
affinity for lipid microdomains. In HIV, virion budding depends on binding of TSG101 to the 
PTAP late domain motif located in Gag. TSG101 binding helps the virus usurp and redirect 
the multivesicular budding pathway to mediate virion budding from lipid microdomains in 
the plasma membrane (65). The budded virion matures with cleavage of the polyproteins by 
the virally encoded protease and is now able to bind to a target cell. 
Thus, lentiviruses have a replication cycle that promotes lifelong persistence in the 
host by production of genetic and antigenic variants, by integration in the host genome, and 
by regulation of viral gene expression. These aspects of virus replication, among others, all 
contribute to evasion of the host immune response. 
Mechanisms of Lentiviral Immune Evasion and Persistence 
Vigorous cellular and humoral immune responses are elicited during early stages of 
lentiviral disease. However, virus manages to escape from both cytotoxic T lymphocytes 
(CTL) and neutralizing antibody, leading to progressive disease in most cases. The diversity 
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of the viral variants and the inherent ability of lentiviruses to generate mutantions are aspects 
of the viral population and virus replication that continually challenge the host's immune 
response. However, it is not just the continual onslaught of novel variants that contributes to 
immune evasion. Many variants differ in biological properties that also enhance or mediate 
immune evasion. 
Lentiviral infection results in virus persistence with ongoing viral replication in the 
infected host. Emergence of genetic and antigenic escape variants thwart cellular and 
humoral immune responses and the expression of an envelope complex that minimizes its 
immunogenicity through several mechanisms are well characterized features of lentiviral 
immune evasion. Immunosuppression, a result of infection with some lentiviruses, such as 
feline immunodeficiency virus and the primate lentiviruses, directly reduces the host's ability 
to mount an immune response. The capacity for regulation of viral gene expression and the 
recent characterization of sanctuary sites that harbor latent virus are additional factors 
involved with lenti virus persistence. An understanding of these and other mechanisms of 
lentiviral persistence is key to developing effective antiviral agents and vaccine strategies. 
Genetic variation and escape 
Lentiviruses exist in vivo as a population of closely related variants, termed a 
quasispecies. Genetic diversity within the population is due to events inherent in the 
conversion of the viral RNA genome into double-stranded DNA during reverse transcription. 
Reverse transcription is mediated by an RNA-dependent DNA polymerase, reverse 
transcriptase (RT), which has a high error rate and lacks proof-reading capacity. Mutations 
arise during each cycle of viral replication as a result of a number of different RT-mediated 
mechanisms. For example, RT has been demonstrated to undergo strand transfer, from a 
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donor viral RNA template to a copackaged acceptor genomic viral RNA template, or to other 
viral or cellular RNAs during DNA synthesis (19,39). The error rate for HTV-1 RT is 
estimated to be on the order of 10"4 (26,51). Since the HIV-1 genome is approximately 104 
bases in length, there is on average one base pair misincorporation per cycle of viral 
replication. As billions of cells may be infected each day in a chronically infected HIV-1 
individual, every possible point mutation may be generated thousands of times in a day (39). 
Thus, considering the error prone nature of RT and its ability to undergo template switching, 
errors may manifest as transitions, transversions, insertions, deletions, and duplication of 
viral nucleic acid. The net effect is a diverse quasispecies capable of a rapid response to 
selective pressures exerted by the host. 
Escape from cellular Immunity. Cellular immunity is mediated by T cells, which 
undergo differentiation in the thymus to express T cell receptors specific for small peptides 
presented by major histocompatibility complex (MHC) molecules. Peptides derived from 
cellular components or from a virus infecting the cell are presented by MHC class I 
molecules on the cell surface. These peptides are recognized by CD8+ T cells, which respond 
by destroying the cell by cytolysis, releasing cytokines, or both (102). In many viruses, 
concomitant CTL activity and resolution of the acute phase of viral replication occur early 
after virus infection, suggesting that CTL responses may select for viral variants capable of 
escaping recognition by CTLs. Variants capable of escape of CTL responses have been 
demonstrated in mice infected with lymphocytic choriomeningitis virus (76). Among 
lentiviruses, the SIV model provides good evidence of CTL escape. In rhesus macaques 
chronically infected with SIV, epitopes within Env and Nef were identified for which 
recognition by CTLs was reduced by amino acid substitutions in these viral proteins late in 
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infection. Analyses revealed positive selection only within MHC-I restricted epitopes 
(28,29). Similarly, in acute disease, epitopes to a molecularly cloned SIVmac239 restricted 
by MHC-I underwent considerable sequence variation within 2 months post inoculation (61). 
Collectively, these results suggest that CTL responses select for escape variants. 
In vitro experiments suggest that amino acid differences in CTL epitopes can 
abrogate binding by the CTL, interfere with binding of peptide to MHC, and/or decrease the 
stability of the peptide-MHC interaction. Other mechanisms that also mediate escape from 
CTL include loss of recognition by the corresponding T cell receptor, faulty processing of 
peptide, and T cell receptor (TCR) antagonism (39). In the latter, the viral CTL epitopes 
interact with the TCR but do not give a stimulatory signal. Instead they act as antagonists, 
rendering the CTL nonfunctional. Thus, numerous mechanisms can contribute to inhibition 
of cellular immune processes. 
Escape from humoral Immunity. In addition to viral escape from CTL, studies have 
suggested that lentiviruses effectively escape the humoral response. However, despite many 
different assays which can measure in vitro antigen-antibody interactions, it has been 
difficult to determine the relative value of these assays in assessing virus control in vivo. 
Many factors contribute to the antibody-antigen interaction. The specificity of antibody for 
antigen is chief among them and, within the context of virus neutralization by serum 
antibody, in vitro activity generally correlates well with protective activity in vivo, with an 
antibody affinity and avidity of approximately 10* to 1010 liter/mol (102). However, for a 
given antibody response, the relative importance of affinity (binding of one antibody site), 
avidity (combined binding strength of the molecularly interlinked binding sites), 
concentration of antibody in serum or tissue, and somatic mutation of antibody is unclear in 
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effectuating the antibody response (34,102). In cases of infection by non-cytopathic viruses, 
slow affinity maturation may enable the host antibody response to adapt to viral variation by 
selection of somatic point mutations in the binding regions of specific IgG receptors of B 
cells. Affinity maturation may therefore also be important in establishing antibody memory 
and a robust antibody response during chronic infection (102). 
Despite the uncertainty of in vivo virus neutralization based on in vitro assays, 
passive transfer experiments have been useful in establishing a correlation between in vivo 
protection from infection by SIV or the chimeric Simian/human immunodeficiency virus 
(SHTV) and in vitro experiments measuring inhibition or reduction of infection of cultured 
target cells (2,31,52,60,87). Nonetheless, the exact mechanisms by which neutralizing 
antibodies control lenti virus replication in vivo remain poorly understood. Notwithstanding, 
since functional assays have been predicted to be better indicators of immunological 
specificity than binding assays, they are frequently used to evaluate humoral immune 
development (102). Determination of inhibition of virus replication by antibodies is generally 
performed by incubating a known amount of virus with serial dilutions of serum and then 
adding the virus/serum mixture to appropriate target cells in vitro. The neutralization titer is 
then calculated as the reciprocal of the highest serum dilution that reduces inactivity by a 
given percentage (often ranging between 50-90%) compared with pre-immune or other 
control serum. 
Escape variants promote persistence. Evidence that neutralizing antibody 
contributes to control of virus replication is the appearance of neutralization resistant viral 
variants. Convincing evidence for in vitro examples of escape from neutralizing antibody has 
been documented where antibody of known specificity was incubated with virus resulting in 
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amino acid changes within the antibody binding domain (40). Other studies have 
demonstrated that amino acid changes outside antibody binding sites that alter the shape of 
the envelope complex may also confer resistance to neutralization (68,97). Such changes 
have also been able to confer resistance to broadly active antibodies (68). 
Evidence for in vivo escape from neutralizing antibody is less clear. Escape from 
neutralizing antibody has been inferred when there is a temporal correlation between the 
development of a neutralizing antibody response and the subsequent appearance of variants 
resistance to neutralization. For lentiviral infections, emergence of antigenic escape variants 
was proposed by Kono in 1973 (44), who suggested that equine infectious anemia virus 
(EIAV) underwent antigenic drift due to antibody-mediated selective pressure. He further 
postulated that antigenic variation was responsible for the recurrent clinical episodes 
characteristic of EIAV infection (44). Other work supported this model of antigenic variation 
during disease caused by EIAV (69,70,82); however, several studies suggested that the 
kinetics and development of neutralizing antibody are more complex (12,13,34). In HIV-1, 
documented escape from neutralizing antibody has been difficult to corroborate at the genetic 
level; however, accidental inoculation of a laboratory worker with a tissue culture adapted 
strain (HIV-1 1I1B) has provided an example of in vivo HIV escape. A neutralization-
resistant phenotype developed in this person and was accompanied by progressive disease, 
suggesting that antigenic variation and development of neutralization resistance do occur in 
humans infected with HIV (4). Normally, however, studies examining antigenic variation of 
HTV have been complicated by several unknowns (genetic composition of the inoculum, date 
of infection, elapsed time of infection, etc.) and antiretro viral drugs. These factors thwart 
efforts to correlate genetic changes with development of neutralizing antibody in the patient 
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As a consequence, animal models of lentiviral disease have been particularly informative in 
understanding development of antigenic escape mutants. 
SIV has been a useful model for the study of antigenic variation. A molecularly 
cloned virus of known genotype, SIVmac 239, was used to infect rhesus monkeys. Sequence 
analysis of the envelope indicated a high ratio of nonsynonymous to synonymous nucleotide 
changes (>95%), which indicated evolution under high selective pressure. Variant genotypes 
from sequential serum samples were inserted into the parental genome and the chimeric 
viruses were assessed using autologous serum for neutralization assays. It was clear that 
monkeys could easily neutralize virus from the starting inoculum, but not from later time 
points. This experiment established that SIV escape mutants to neutralizing antibody arose 
during infection (7). It was less clear if escape from neutralizing antibody occurred during 
disease progression. Nonetheless, the concept of escape from neutralizing antibody suggests 
another possible mechanism of lentiviral persistence. 
Structural features of the HIV envelope that promote immune evasion 
The crystallized structure of the HIV envelope has facilitated understanding how the 
assembled trimer avoids immune detection. The structure of the HIV envelope has important 
consequences in receptor binding and antigenicity. It is arranged as a trimer of SU and TM 
dimers. The amino acid sequence of HIV SU is organized into five variable regions (V1-V5) 
interspersed between conserved regions. The first four variable regions exist as loop 
structures anchored to the SU core by disulfide bonds. The SU core is composed of an inner 
domain, an outer domain, and a bridging sheet. The bridging sheet, located between the two 
domains, is composed of an antiparallel p-sheet with structural contributions from the fourth 
conserved region and the V1/V2 stem. The V3 loop base is located in close proximity to the 
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V1/V2 stem. The crystallized structure of the gpl20 core, lacking the variable loops, 
complexed to CD4 and a neutralizing antibody has greatly aided in understanding the events 
involved with binding of antibody to SU and with receptor binding (98). 
The inner and outer domains and the bridging sheet all contribute to CD4 and 
chemokine receptor binding (98). The CD4 binding site to the core is flanked by the VI/V2 
stem. CD4 binding induces structural alterations that expose the chemokine receptor binding 
site. Importantly, CD4 binding repositions the VI/V2 stem, rearranging the P-sheet between 
the inner and outer domains, allowing CCR5 binding. The CCR5-binding site is located near 
the bridging sheet and V3 loop residues (77). Alterations in residues in both the bridging 
sheet and V3 are associated with co-receptor usage (77,98). There is also evidence that 
suggests that chemokine receptor binding also induces conformational change in the 
envelope complex that leads to exposure of the TM ectodomain (77). 
Conformational changes in the envelope complex that occur upon receptor binding 
also have important implications for immune evasion. For example, CD4 binding to the 
recessed pocket ensures transient exposure to the chemokine receptor binding site and 
sterically restricts antibody binding (98). Although CD4 binding does expose epitopes for 
neutralizing antibody (CD4-induced epitopes), the V1/V2 and V3 loops are in close 
proximity and shield this region. In addition, the region containing CD4-induced epitopes is 
itself hypervariable, suggesting immune evasion through variation in protein sequence. 
Three faces of SU have been defined that correlate with susceptibility to neutralizing 
antibody. The non-neutralizing face is situated on the inner aspect of the SU trimers, contains 
the CD4 binding site, is poorly accessible to antibody, and induces non-neutralizing 
antibodies. The neutralizing face contains the V2 and V3 loops and the region of CD4-
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induced epitopes. The immunologically silent face corresponds to the heavily glycosylated 
outer domain that is also highly variable (98). Thus, the structural changes that occur in the 
envelope complex at different stages of binding and fusion have important implications for 
immune evasion as well. 
Masking 
In order to reduce exposure of epitopes to the immune system, the HIV-1 envelope 
has evolved several different structural features that mask the presence of epitopes. The 
structure of the envelope complex itself, the placement and variation of asparagine-linked 
carbohydrates, as well as presence of variable domains near immunodominant sites all 
contribute to masking of neutralization sensitive epitopes. 
Despite being highly exposed to the immune system, the HTV-1 envelope has evolved 
structural features that reduce antibody access to epitopes on the envelope. Since binding of 
virion to host cell is mediated through interactions of SU and the cellular receptors, the 
envelope's structure plays a role in both virus replication and immune evasion. The fact that 
these two envelope associated functions likely impose different physical constraints on SU is 
suggested by an increase in replicative fitness in cultured cell lines when no immune forces 
are present (8,39). However, these cell-adapted viruses also tend to be more susceptible to 
neutralization by antibody compared with wild-type strains (8,40). 
Further evidence that immune evasion and receptor binding exert different selective 
forces on the SU complex comes from studies in HIV which have examined the two-receptor 
mechanism. HIV binds its receptor, CD4, which induces conformational changes in SU that 
permit binding to a chemokine receptor, usually CCR5 or CXCR4. The conformational 
changes induced in SU upon CD4 binding reveal epitopes to broadly neutralizing antibodies, 
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termed CD4-induced epitopes (39,46,92). Shielding epitopes from host surveillance is also 
supported by observations that CD4-independent viruses are extraordinarily sensitive to 
neutralizing antibody (41). Additionally, a mechanism of conformational masking has been 
studied which partially explains how HIV-1 maintains receptor binding and simultaneously 
resists neutralization (45). Conformational masking is a means by which epitopes to 
neutralizing antibody that are located near the binding site for CD4 are protected because 
antibodies to these epitopes face an energetic handicap for binding that other neutralizing 
antibodies to HTV SU do not (45). Thus, HIV has evolved mechanisms that enable it to 
maintain receptor binding while simultaneously resisting neutralization. 
Another viral strategy of avoiding immune detection includes occlusion of conserved 
domains within the SU oligomer. Two faces of SU were identified: one face was determined 
to be buried within the trimeric configuration of the SU complex and contained epitopes 
recognized by antibodies not capable of neutralizing virus (non-neutralizing face); the other 
face contained epitopes that reacted with envelope oligomers and neutralized virus 
(neutralizing face) (8). Thus, the oligomeric structure of the virus is capable of restricting 
exposure of potential neutralizing epitopes once assembly of the envelope complex is 
complete. 
Interestingly, lentiviruses have developed a number of strategies to minimize 
recognition by neutralizing antibodies to epitopes on the neutralizing face. One mechanism is 
extrusion of variable domains from the exposed surfaces of the SU complex. Many 
lentiviruses, including EIAV, contain discrete regions of hypervariability in the envelope 
(1,5,47,67,99). Many of these regions are predicted to exist as loops, as they are flanked by 
cysteine residues that can form intrachain disulfide bonds (39). Variable loops have been 
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hypothesized to shield conserved regions of SU containing neutralizing epitopes as HTV-1 
and SIV isolates that lack the VI and or V2 loops are extremely sensitive to neutralization 
(9,40,90). 
Extensive glycosylation of the envelope also contributes to immune evasion by 
shielding neutralization sensitive sites on the SU protein. Asparagine-linked oligosaccharides 
can be attached cotranslationally to proteins provided the motif NXS/T is present, where X 
may be any amino acid. Fifty-percent of the envelope's mass may be N-glycans; such 
glycosylation has been shown to alter the immunogenicity of viral surface proteins of many 
viruses, including lentiviruses (39). Changing the number of N-glycans, or changing the 
placement of N-glycans can alter the neutralization phenotype of the virus by altering 
exposure of epitopes (17,40,66). Alteration of the NXS/T motif of the V3 loop of HIV to 
eliminate N-glycan attachment rendered the virus extremely sensitive to neutralization (83). 
Further evidence for the importance of N-glycans in shielding epitopes comes from studies 
where N-glycan deficient virus grown in the presence of V3-directed neutralizing antibody 
selected for gain of an N-linked glycosylation site (83). Thus, N-glycans, which appear as 
self to the host, are an important means of shielding epitopes from neutralizing antibody. 
In summary, evasion of the humoral immune response by HIV may be mediated by 
occlusion of the oligomer, mutational variation, carbohydrate masking, and conformational 
masking. All of these mechanisms successfully limit exposure of epitopes for neutralizing 
epitopes and contribute to virus persistence. 
Interference with immune cell function 
During acute infection, the majority of HIV infected cells are CD4+ T cells and these 
are rapidly destroyed in vivo by immune mediated mechanisms, antibody-dependent cellular 
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cytotoxicity, and bystander-effects (39,80). This may irreversibly cripple helper T cell 
function, which in turn, has negative consequences for CTL and B cell responses. However, 
patients that receive highly active antiretroviral therapy (HAART) during acute infection 
may preserve a certain level of helper T cell function, thereby forestalling progression to 
AIDS (80). These findings suggest that loss of CD4+ T cells early in infection hampers 
appropriate maturation of the immune response, providing another mechanism of persistence. 
In addition to hampering immune maturation by compromising helper T cell function, 
the primate lenti viruses also inhibit efficient processing and presentation of viral epitopes. 
Primate Antiviruses contain more genes than the other complex lenti viruses, including vif 
vpu, vpr, vpx, and nef The nef gene product, a small myristoylated protein, has been shown 
to contribute to high viral titer and progression of disease (39,86). It does so through several 
mechanisms including reduction in the number of MHC class I molecules expressed on the 
infected cell's surface, and interference with the endocytic sorting machinery of the cell 
(39,92). Reducing the number of MHC class I molecules on an infected cell's surface would 
decrease the presentation of viral epitopes to CTLs, thereby decreasing the likelihood of host 
cell lysis (22). It has been speculated that delaying cytolysis, as opposed to complete 
inhibition of cytolysis, would be sufficient to allow the viral replication cycle to progress to 
release of virions (39). Thus, interference with MHC class I regulation by nefhas a direct 
impact on viral persistence and pathogenesis. 
Besides activated T cells and macrophages, HIV replication has been detected in 
naïve CD4+ T cells, CD8+ T cells, monocytes, and NK cells, all of which are important in 
host immunity and express sufficient levels of CD4 and coreceptors for infection(6). The 
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importance of these cell types in disease progression and in acting as a viral reservoir is the 
focus of ongoing studies (6). 
Viral reservoirs promote persistence 
Viral reservoirs are defined as cell types or anatomic sites where a stable, replication 
competent virus pool accumulates, thus assuring a population of infected cells in the future 
(6,75). In HIV-1, the best evidence for a viral reservoir is infected, resting memory CD4+ T 
cells (30). Infection of these cells is dependent upon the level of coreceptor expressed, either 
CXCR4 or CCR5. CCR5 is expressed at low levels, but sufficiently in some cells for 
infection; CXCR4 is expressed at sufficient levels on all memory CD4+ cells. HIV infection 
of CD4+ T cells may result in either preintegration or postintegration latency depending on 
the stage of development of the CD4+ T cell at the time of infection. Preintegration latency 
results from infection of lymphoblasts that are in the process of reverting to a resting state. 
Unless these cells are antigenically stimulated, this compartment of infected cells will decay 
within a week (6,75). Postintegration latency occurs when an infected lymphoblast avoids 
both the cytopathic effects of the infection and host cytolytic effector mechanisms, and goes 
back to a resting state. This compartment of resting CD4+ T cells is very stable, with a half-
life of 44 months, and is maintained by a process of proliferative renewal. In this instance, 
persistence is thought to involve cell division and not viral replication (6,75). Since infection 
of reverting lymphoblasts may occur throughout infection, this reservoir has been 
characterized as an archive of viral genotypes that were previously circulating at high titer. 
These cells contain integrated pro viral HIV DNA; however, since they are in a resting state, 
there is little or no expression of viral genes. It has been hypothesized that a lack of cellular 
transcription factors, NFkB chief among them, accounts for lack of gene expression. 
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Therefore, HIV latency is a consequence of tropism for CD4+ T cells, a small population of 
which revert to a resting state no longer permissive for virus replication(6,75). 
In contrast to HIV, SIV, and feline immunodeficiency virus (FTV), infection with 
EIAV does not result in immunodeficiency. In fact, infection with EIAV may result in a 
rapid onset of recurrent episodes of clinical disease that are eventually brought under control 
by the immune system. Nonetheless, there is ongoing virus replication during clinical 
quiescence. Therefore, EIAV infection of horses provides a lentiviral model for examining 
host-pathogen interactions that are necessary for virus persistence in an immunocompetent 
host. 
Equine Infectious Anemia as a Model of Lentivirus Persistence 
Infection of equids with equine infectious anemia virus results in lifelong lentiviral 
infection. In contrast with other lentiviruses, however, EIAV infection can result in clinical 
disease early during the course of infection with progression to inapparent disease. During 
the inapparent stage of disease the horse appears clinically normal despite the presence of 
ongoing virus replication. This virus therefore offers a model for characterization of the 
genotypic and phenotypic differences associated with persistence that occur during clinical 
and subclinical infection. EIAV also has important ramifications for horse owners as it is a 
USDA regulated disease. Although the disease is less prevalent now, it remains a concern for 
equestrians and the veterinary community. 
History and Geographic Distribution 
The disease, equine infectious anemia (EIA), has been recognized as a clinical entity 
since the early 1800s, first characterized in 1843 by Ligné in France as anhémie du cheval 
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(27,49). Other names used to refer to the disease in English include: infectious anemia of 
horses, swamp fever, equine pernicious anemia, pernicious anemia of horses, equine 
relapsing fever, equine malaria, American surra, malarial fever of horses, Manitoba disease, 
Mountain fever, No-name disease, Loin distemper, River bottom disease, and Wyoming 
disease (27). The names hint at both the clinical profile and the geographic distribution of the 
disease. 
Prior to the automobile, the horse was widely used in commerce and transportation. 
As a result, equine infectious anemia had a considerable impact in local economies. For 
example, in certain regions in Northeastern France, upwards of 50% of the cart-horse 
population was estimated to be affected. Throughout the mid nineteenth century and through 
World War I, however, much of Europe experienced similar epizootics. As a disease with 
practical importance for everyday life, anhémie du cheval was widely studied. In 1904, 
Vallée and Carré at the Ecole vétérinaire d'Alfort, published the results of studies that 
demonstrated the infectious nature of the disease and implicated a filterable agent, believed 
to be a virus, as the etiologic agent. Thus, equine infectious anemia virus (EIAV) was the 
first lentivirus isolated (14,19,27). Other investigators throughout the world later confirmed 
the results of Vallée and Carré and characterized the disease. By World War 0, EIA had been 
recognized in Europe, North America, South America, Asia, Africa, and small islands off the 
coast of Australia (27). 
Early accounts of the disease, regardless of geographic distribution, were very 
similar. Apart from the rapidly fatal and inapparent phases, the main features included 
intermittent fever attacks, depression, progressive debility, emaciation, and dependent edema. 
On the basis of frequency of febrile cycles, Vallée and Carré divided the disease into acute, 
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subacute, and chronic stages (15,16). Acute EIA was understood to be severe and unrelenting 
for 5-15 days, often terminating in death. Subacute disease was less severe, punctuated with 
clearly defined remissions, and lasted weeks to months. Horses with chronic disease had few, 
mild fever episodes but progressive anemia (27). The nomenclature currently used to 
describe the stages of disease has been redefined. The acute stage of disease is understood to 
be associated with the initial burst of viremia while the chronic stage of disease is analogous 
to the subacute stage defined by Vallée and Carré. Today, the inapparent stage of disease, 
where the horse appears clinically normal, most closely resembles the previous definition of 
the chronic stage of disease. In Vallée and Carré's day, it is probable that fewer horses 
actually progressed to become true inapparent carriers since most were used as work animals. 
In fact, Hutyra, Marek, and Manninger (27) later added that one animal could experience all 
three stages of clinical disease, become clinically normal, but then undergo acute, fulminant 
disease. The latter occurrence was often associated with stress, such as strenuous labor, 
inclement weather, surgery, and profuse blood loss (27). 
Since publication of the experiments performed by Vallée and Carré, efforts were 
made to identify and reduce the number of affected horses. Development of the "Coggins 
test" by Dr. Leroy Coggins at Cornell University (20,21) greatly facilitated identification of 
horses infected with the virus, and represented a milestone in control of the disease. Efforts 
to understand the pathogenesis and mechanisms of persistence of EIAV were already 
underway when the virus causing acquired immunodeficiency syndrome (AIDS) was 
identified. Investigators tasked to human immunodeficiency virus (HIV), a lentivirus sharing 
a genome organization similar to that of EIAV, gained insight into HIV through animal 
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lentiviral models, including EIAV. Today, the EIAV infection model remains important in 
understanding mechanisms of lentivirus pathogenesis and persistence. 
"Le traitement curatif est loin d'être couronné d'un plein succès. " 
"The curative treatment is far from being crowned with full success." 
Dr. Ligné, médecin vétérinaire, à Joinville (Haute-Marne, France, 1843X49) 
Clinical signs and disease 
Lentiviruses are generally associated with chronic, progressive diseases of insidious 
onset of the hematological and neurological systems of animals and man (92). In contrast, the 
onset of clinical disease produced by EIAV infection is usually rapid, with clinical signs 
occurring within one to four weeks after infection. However, clinical outcome to infection is 
variable and is probably due to a combination of host factors, the virulence of the virus strain, 
and the infecting dose. Consequently, EIAV infection may result in subclinical disease, or 
clinically apparent disease ranging from mild to severe. 
The acute stage of disease is associated with the initial viremic burst and usually 
occurs within one to four weeks of infection. Common signs include high fever (up to 107°F, 
41.6°C), severe thrombocytopenia, depression, and inappetance. Severely thrombocytopenic 
horses may develop mucosal petechiations, epistaxis, and ventral pitting edema and 
subsequently die (25). Most horses, however, survive the acute stage and undergo a brief 
recovery period (5 fo 30 days) during which levels of plasma viremia decrease substantially 
and clinical signs resolve. The chronic stage follows and is characterized by recurring, 
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intermittent cycles of viremia, fever, thrombocytopenia, and depression, which typically 
decrease in severity over approximately one year. The recurrent nature of the disease is, in 
part, due to antigenic viral variants which, unrecognized by the immune system, allow 
temporary escape from the immune response and thereby allow replication to high titer of 
that variant (25,44). Horses may survive the chronic stage of disease and progress to the 
inapparent carrier stage, die during the recurrent disease episodes (as during the acute stage), 
or progress to a debilitating form of the disease characterized by ill-thrift, anemia, ventral, 
pitting edema, progressive weight loss (a "swamper"), and ultimately death (25). Progression 
to the inapparent carrier stage is temporally associated with maturation of the humoral and 
cellular arms of the immune system. However, virus replication persists in the face of a 
mature immune response. The level of virus replication that occurs in inapparent carriers is 
sufficient for transmission of virus and may be lethal to the newly infected horse (84). 
Transmission 
Vector borne transmission is the most common means of EIAV transmission, with 
tabanids (horse flies, deer flies) being the primary vectors (38). The virus does not replicate 
in the insect; however, virus can remain infectious in the blood associated with the tabanid's 
proboscis for several hours, and can be mechanically transferred to another horse (38). 
Additionally, iatrogenic transmission with blood contaminated needles, surgical instruments, 
teeth floats, nasogastric tubes, etc. serving as mechanical vectors is possible. Risk of 
transmission to uninfected horses is increased when the source of infected blood is a horse 
undergoing clinical disease. Transplacental, colostral, lactal, and venereal transmission have 
also been documented. Foals bom to infected dams may acquire antibody to the virus via 
colostral transfer. As maternal antibody wanes, the antibody titer to EIAV wanes in 
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uninfected foals and a qualitative difference in the AGID reaction can be observed over time. 
Foals bom to mares undergoing severe disease manifestations during gestation are more 
likely to be infected. Inapparent carrier horses, despite appearing clinically normal, can 
maintain low to moderate levels of replicating virus in the blood and therefore can serve as a 
reservoir for infection of other horses (37,85). 
Clinical pathology and necropsy findings 
The clinicopathologic findings of EIA are variable, depending on the stage of disease, 
and largely reflect activation of the host immune response. Thrombocytopenia is the most 
consistent finding and is believed to be partly mediated by IgG and IgM binding to platelets 
with subsequent removal from the circulation by tissue macrophages of the liver, spleen, and 
lymph nodes (18). Additionally, it is believed that circulating platelets are activated and 
hypofunctional (81), and that the virus causes a noncytocidal suppression of platelet 
production (24,96). Activated platelets can aggregate or degranulate, both events leading to 
removal of platelets from the circulation. Increased levels of the cytokines TNF-a, TGF-P, 
and IFNy, all negative regulators of platelet production, have been found immediately prior 
to the onset of thrombocytopenia during acute disease, suggesting another mechanism of 
decreased megakaryocytopoiesis and thrombocytopenia (94). The anemia variably associated 
with chronic recurrent disease, and commonly with the chronic, debilitating form of disease, 
is due to several different mechanisms. The virus is capable of inhibiting bone marrow 
erythropoiesis. Additionally, virus or virus-antibody complexes may adsorb to erythrocytes, 
activate complement, and result in intravascular hemolysis. Also, complement-coated 
erythrocytes may be phagocytosed, resulting in extravascular hemolysis. Horses with 
moderate to severe hemolysis may develop hyperbilirubinemia and icterus (84). The 
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Coombs' test, which tests for the presence of antibodies on the surface of erythrocytes, may 
be positive during episodes of disease. Increases in erythrocyte lactate dehydrogenase and 
glucose-6-phosphate dehydrogenase reflect a regenerative marrow response to anemia. A 
hypergammaglobulinemia is also documented in most horses, including inapparent carriers 
(78). A mild leukopenia, lymphocytosis, and monocytosis may be associated with active 
disease (84). 
Horses that die of clinically severe EIAV infection may have the following 
pathological changes, which reflect the immunopathogenesis of the disease: 
lymphadenopathy, splenomegaly, hepatomegaly, pronounced hepatic lobular architecture, 
mucosal and visceral ecchymoses, ventral subcutaneous edema, and small vessel thrombosis. 
Histopathology typically reveals a mononuclear cell infiltrate of periportal regions of the 
liver, as well as in the adrenals, spleen, lymph nodes, meninges, and lungs. 
Hemosiderophages are typically found in the lymph nodes, liver, spleen, and bone marrow. 
Immune complex deposition in renal glomeruli and thickened tufts are common findings 
(84,85). 
Diagnosis 
The U.S. Department of Agriculture has approved three diagnostic tests for detection 
of EIAV infection, all of which assay for viral antibody. These include the agar gel 
immunodiffusion (AGED) test, more commonly known as the Coggins test (20,21), the 
competitive enzyme-linked immunosorbent assay (C-ELISA), and the synthetic-antigen 
ELISA (89). Other tests which assay for antibody to viral (glycoproteins include the 
Western blot and fluorescence polarization. The fluorescence polarization assay is a simple 
and rapid technique that may gain usefulness as an approved diagnostic test (93). Another 
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potentially useful diagnostic test, polymerase chain reaction (PGR), is based on detection of 
viral nucleic acid, either viral RNA (in virions), or pro viral DNA (integrated in the host 
chromosome) (59). This test is very specific but may result in a false negative result if the 
primers used differ from the actual viral genetic sequence. 
Control 
No treatment or USDA approved vaccine is currently available for EIAV infection; 
therefore, control measures, which are largely determined by individual states, are critical for 
restricting spread of disease. Most states require that a horse be seronegative within six 
months to a year of entry into the state. Many states also require seronegativity for 
participation in equestrian events such as shows, races, etc. Despite these requirements, it is 
estimated that as few as twenty percent of the equine population are ever tested. As a result, 
reservoirs of infected horses are maintained and the actual prevalence of EIAV infected 
horses in the United States remains unknown. It is well established, however, that there are 
regional differences in climate that favor the vector, and consequently, infection. The states 
bordering the Gulf of Mexico have the highest incidence of the approximately 2000 
seropositive cases reported annually. 
If a horse is seropositive (a reactor), then an orchestrated series of regulatory events 
occurs which may vary from one jurisdiction to another. State regulatory officials are 
contacted first in order to establish a quarantine of the premises and to promptly retest the 
reactor. The owner and testing veterinarian are then notified. All horses on the premises are 
necessarily tested; horses which test positive are retested to confirm positivity. Repeated 
testing at 45 to 60 day intervals under quarantine generally continues until 45 to 60 days after 
all remaining horses tested are seronegative; the time period is to allow for seroconversion of 
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recently infected horses. Additionally, horses which had significant exposure to the infected 
horse(s), either at an equestrian event, or that were known to have spent time at the premises 
under quarantine, are sought and tested. Reactors may be euthanized, donated to an approved 
research institution, or maintained in permanent quarantine. Reactors maintained in 
quarantine must be permanently marked, usually over the right shoulder or neck, with the 
letter 'A' preceded by the state's USDA identification number, and followed by a number 
assigned to the horse. Reactors are prohibited from interstate travel unless USDA approval is 
granted for shipment in "sealed containers." 
Control measures for horse farms and ranches should begin with sérodiagnostic 
testing of all horses on the premises with annual testing of permanent residents; regions with 
a high disease incidence should consider testing all residents biannually. All new horses to 
visit or take up residence on the premises should be seronegative within a three to six month 
period prior to arrival. Horses which have a negative test result obtained in less than a 45-60 
day period prior to arrival may not have had enough time for seroconversion if recently 
infected; these horses should be retested if accepted onto the premises. Fly control should be 
practiced and avoidance of iatrogenic spread of infection, by veterinarians and their clients, 
should be strict. All equestrian events should require proof of seronegative status; equestrians 
should encourage organizers of local events to adopt such a policy. 
Since there has never been a federal eradication program in force for EIA, the 
persistence of reservoirs of EIAV infected horses must be expected. Clients who face 
euthanasia or lifetime quarantine of an inapparent carrier of EIAV often find it difficult to 
understand the threat their horse poses to other horses. They are often equally frustrated by 
the financial and emotional losses. It is the veterinary community's responsibility to educate 
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horse owners about the disease and its potential consequences so that outbreaks may be 
limited by rigorous voluntary surveillance testing. 
Genetic and antigenic variation during clinical disease of EIAV 
Kono (44) proposed that the periodicity of the clinical episodes of equine infectious 
anemia was the result of immune selection by neutralizing antibody of antigenic viral 
variants. His analysis of serum samples obtained during sequential febrile episodes indicated 
that virus was not susceptible to previously formed neutralizing antibody, but would react 
with antibodies produced weeks later. He proposed that EIAV underwent antigenic drift, with 
antigenic variants arising due to antibody-mediated selective pressure and further postulated 
that this mechanism was responsible for periodic febrile relapses and persistent viremia 
(42,44). Salinovich et al. examined viruses from successive febrile episodes by peptide and 
oligonucleotide mapping and correlated differences in the virus genotype with differences in 
neutralization phenotype. Payne et al. performed the first sequence analysis of the EIAV 
envelope, detecting differences in nucleotide and amino acid sequence at successive febrile 
episodes (70). Following studies indicating that the viral envelope contains distinct antigenic 
sites (36), Payne et al. provided the initial work of mapping epitopes to neutralizing and non-
neutralizing antibodies, a step toward understanding where conserved and variable 
immunogenic sites are within the envelope (72). Since then, two neutralizing epitopes have 
been mapped to the EIAV V3 region, which has been referred to as the Principal Neutralizing 
Domain, or PND (3,47,67,101). In addition, several studies have reported size variation in 
the EIAV V3 region associated with changes in antigenicity (35,47,67,101). A third epitope 
for neutralizing antibody was shown to be partially contained in the V5 region (3). The 
finding that neutralizing epitopes are contained within variable, immunodominant regions of 
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the envelope supports a role for genetic variation in providing the virus with a mechanism to 
evade host immune factors. Despite observations of antigenic and genetic variants at 
successive febrile episodes, a causal relationship between these differences and neutralizing 
antibody was not established. 
Carpenter et al. demonstrated with a heterogeneous, wild type virus that several 
febrile episodes occurred before neutralizing antibody could be detected, suggesting that 
neutralizing antibody might not be the sole mechanism for generation of antigenic variants 
(12,13). They proposed that antigenic variation could arise from immune recognition and 
destruction of virus-infected cells. They were unable to demonstrate a role for neutralizing 
antibody in immune selection of EIAV variants during the early stages of disease, further 
suggesting that generation of antigenic variants is not due solely to the selective pressure of 
neutralizing antibody. The development of cytotoxic T-lymphocytes specific for EIAV 
variants has been correlated with resolution of the initial febrile period (57), indicating that 
cell-mediated immune responses maybe important in variant selection. However, other 
studies have failed to demonstrate that variation in immunodominant regions of env is due to 
selection by variant-specific CTL (33). Notwithstanding, MHC-restricted CD8+ CTL have 
been detected following experimental infection and were present after viremia terminated 
(57). Since the introduction ofKono's model of antigenic variation, numerous studies have 
examined genetic and antigenic variation in the SU in viruses which are temporally linked 
with the recurrent cycles of fever during the acute and chronic stages of infection 
(43,44,69,70,82). However, the causal link between genetic variation and immune selection 
of variants has not been well established. For example, longitudinal studies of EIAV 
evolution in experimentally infected ponies have reported emergence of antigenic variant 
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virus in the absence of neutralizing antibody (12,79). Moreover, variants that emerge in the 
absence of neutralizing antibody show significant variation in the immunodominant domains 
of SU (79). Together, these findings suggest that the virus may be able to obviate 
development of an effective neutralizing antibody response. 
Both cellular and humoral immune responses contribute to suppression of viral 
replication during inapparent stages of infection (33,34,82). Immunological control is 
associated with the broadening and maturation of the immune response, although no subset 
of the immune response has been shown to specifically correlate with restriction of virus 
replication during long term persistence (33,34). A major gap in our efforts to understand the 
correlates of immune protection is that the vast majority of reports characterizing the role of 
env variation in immune evasion and virus persistence have failed to examine virus 
genotypes present during periods of clinical quiescence. In the absence of such studies, it is 
not possible to fully evaluate the importance of antigenic variation and escape from immune 
surveillance as a mechanism of EIAV persistence. Thus, while genetic changes in SU can 
alter antigenicity and enable escape from neutralizing antibody, it is less clear that escape 
from the host immune response plays a significant role in driving virus evolution in vivo. 
EIAV cell tropism 
HTV-1 replicates in vivo in both CD4+ T-lymphocytes and in cells of the 
monocyte/macrophage lineage. Macrophage (M)-tropic virus is the predominant virus found 
during early, subclinical stages of HTV-1 infection. In contrast, T-tropic viruses are most 
often associated with the onset of immunosuppression and progression to clinical disease. 
Thus, in vivo cell tropism is a major correlate of disease progression in HIV-l-infected 
individuals (23). The cell tropism of HTV-1 is determined by coreceptor usage, and maps to 
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the V3 region of env. The receptor(s) for EIAV has yet to be identified, and only one study 
has examined the role of env variation in EIAV cell tropism (73). 
EIAV shares the lentiviral in vivo tropism for cells of the monocyte-macrophage 
lineage (11,62). In addition, EIAV has been demonstrated to replicate in vitro and in vivo in 
endothelial cells (55,63) and can be adapted for replication in fibroblast cells, such as equine 
dermis cells (ED), or kidney cells (11,50,74). In general, strains of virus selected for in vitro 
replication in fibroblasts replicate to higher titers in fibroblast cell lines, and wild type strains 
replicate to higher titer in monocyte-derived macrophage cultures (MDMC). Studies have 
been conducted examining differences in genetic variation in the LTR vis-à-vis fibroblast or 
macrophage tropic virus. Interestingly, genetic variation in the enhancer region altered the 
mosaic of transcription factor binding sites found in the enhancer region (10,48,53,54,56,73). 
Changes in transcription factor binding sites appeared to correlate with in vitro cell tropism 
(53,56). These results suggested that variation in the LTR enhancer region contributes to cell 
tropism (48). However, recent studies testing the role of the LTR in in vitro cell tropism have 
yielded conflicting results (48,71). Moreover, in vivo analyses indicated that although the 
LTR genotype is an important determinant of virus replication in vivo (48,100), it is less 
clear that the LTR contributes to cell tropism in vivo. These findings raise the possibility that 
other regions of the virus genome may also contribute to EIAV cell tropism in vivo and/or in 
vitro. 
Perry et al. suggested that the SU protein of EIAV was not an important determinant 
of in vitro cell tropism (73); however, their data show clear differences in the rate and level 
of virus production in both MDMC and fibroblasts that are due solely to the changes in env. 
Wild-type viruses that replicate well in primary horse macrophages vary in env genotype 
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when compared with cell culture adapted strains, which are fibroblast tropic and/or dual 
tropic. (55,73). Together, these findings strongly argue that genetic variation in env might 
contribute to changes in cell tropism in vitro and/or in vivo. 
Overall Goal 
The long-term goal of this research was to determine if variation in EIAV SU 
contributes to virus persistence during the inapparent stage of disease. To approach this goal, 
we proposed a genotypic and phenotypic characterization of EIAV SU during clinically 
apparent and inapparent stages of disease in an experimentally infected pony. Our hypothesis 
was that variation in env can alter biological properties of EIAV and confer selective 
advantage during periods of clinical quiescence. 
The specific aims were to: 
1. Identify genetic variation in env at sequential stages of disease in an EIAV 
experimentally infected pony; 
2. Determine if env variation alters type- and/or group-specific neutralizing epitopes; 
3. Determine if genetic changes in SU alter the biology and kinetics of virus 
replication in vitro. 
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CHAPTER 2. CHARACTERIZATION OF VIRAL QUASISPECIES OF THE 
SURFACE UNIT ENVELOPE GLYCOPROTEIN DURING ACUTE, CHRONIC, 
AND INAPPARENT STAGES OF EQUINE INFECTIOUS ANEMIA VIRUS 
INFECTION 
To be submitted to Journal of General Virology 
'Brett A.Sponseller, 'Robert J. Thompson, 'Wendy O. Wood, 2J. Lindsay Oaks, and 'Susan 
L. Carpenter. 
Abstract 
Equine infectious anemia virus (EIAV) infection causes a variable disease course consisting 
of acute, chronic, and inapparent stages of disease. Previous studies have characterized 
genetic variation in the envelope during recurrent febrile episodes of the chronic period in 
EIAV infection, detecting the appearance of novel envelope variants with successive fever 
episodes. Recently, it has become apparent that virus replication continues during the 
inapparent stage of disease at higher titers than previously thought. Genetic and antigenic 
variation in the envelope is considered to play an important role in EIAV persistence; 
however, few studies have characterized variants isolated during the inapparent stage of 
disease. We undertook a longitudinal study of surface unit envelope glycoprotein (SU) 
variation in a pony experimentally inoculated with the virulent, wild-
1 Department of Veterinary Microbiology and Preventive Medicine, Iowa State University 
^Department of Veterinary Microbiology and Pathology, Washington State University 
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type, EIAVwyo- Viral RNA isolated from the inoculum and from sera collected sequentially 
during the acute, chronic, and inapparent stages of infection was amplified by RT-PCR, 
cloned, and individual clones were sequenced. The V2-V7 region was RT-PCR amplified 
and a total of280 clones from the inoculum and 10 time points extending over a two year 
period were analyzed. In the acute stage, the viral quasispecies was relatively homogeneous 
and nearly identical to that found in the inoculum. During the chronic stage, the quasispecies 
was more heterogeneous and was characterized by the accumulation of point mutations in 
previously described SU variable regions. However, genotypes from the acute stage persisted 
in the chronic stage and the overall population was 90-95 percent similar to the inoculum. A 
rapid and significant increase in genetic heterogeneity was observed during the inapparent 
stage of disease, suggesting that diversifying selection is driving variation during this stage of 
disease. Indeed, our analyses indicated a 100 percent increase in quasispecies diversity and 
divergence with progression to the inapparent stage of disease. Variation was characterized 
by deletions/insertions in the principal neutralizing domain, as well as point mutations in 
each SU variable region. Surprisingly, these marked genetic changes did not result in 
recrudescence of clinical disease, as might be expected if immune evasion were the sole 
selective factor, hi fact, semi-nested RT-PCR identified genotypes present in the inoculum 
that arose and became predominant late in the inapparent stage of disease. These data suggest 
that the selective environment during the inapparent stage of disease is distinct from that 
early after infection. 
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Introduction 
Equine infectious anemia virus (EIAV) is a member of the Lentiviridae subfamily of 
retroviruses. Similar to other lentiviruses, EIAV has a complex genome organization, a 
tropism for cells of the monocyte/macrophage lineage, and can establish lifelong persistence 
in the host. However, in contrast to most lentiviruses, EIAV may cause a rapid onset of 
disease characterized by recurrent episodes of viremia, fever, and thrombocytopenia (20). 
Interspersed among episodes of clinical disease are quiescent periods during which no signs 
of disease are evident, and viremia decreases. Anemia and dependent edema may develop in 
horses which experience several episodes of disease (20). Many horses survive the clinical 
episodes, which can recur for approximately a year, and become inapparent carriers of the 
virus. Inapparent carriers are able to control virus replication; however, virus is not 
eliminated (6). 
Previous studies have identified three hypervariable regions of the EIAV genome: 
the long terminal repeat (LTR), the overlapping region of Rev with the envelope 
transmembrane protein (TM), and the surface unit envelope glycoprotein (SU) (1,3,4,16). 
Variation in SU occurs predominantly in 8 hypervariable domains, VI-V8 (13,14). The lack 
of proof-reading capacity of the virally encoded reverse transcriptase (RT) and its ability to 
undergo template switching, result in mutations, insertions, deletions, and duplication of viral 
nucleic acid. The net effect is a population of closely related viral variants, commonly 
referred to as a quasispecies. A quasispecies was originally described as a population of 
related genotypes comprised of a master sequence, the dominant nucleotide sequence within 
the population, and the mutant spectra, an infinite heterogeneous cloud of variants (7). The 
56 
unit of selection is the entire quasispecies (7), and not individual variants, which may be 
short-lived due to movement of the population in a dynamic environment (12). As a result, a 
viral quasispecies is capable of a rapid response to selective pressures exerted by the host. 
Previous studies have examined genetic variation in the SU of EIAV (1,13,15,19,23). 
Most of these studies have been performed with either a cell-adapted inoculum derived from 
a biological clone (13,15) or following in vitro selection of a field isolate (19,23). As a result, 
few studies have characterized genetic variation of a wild-type EIAV quasispecies. 
Furthermore, few long term studies have followed virus evolution during the inapparent stage 
of disease. In the present study we characterized genetic variation within a region of EIAV 
SU that includes variable domains V2-V7. Our study chronicled changes in the quasispecies 
during progression through the acute, chronic, and inapparent stages of disease of a pony 
experimentally infected with EIAVwyo» a wild-type inoculum. Thus, this pony provided an 
opportunity to study viral quasispecies evolution in a system that approximated natural 
lent:viral infection. We found that the inapparent carrier stage of disease was characterized 
by a marked increase in both the diversity and divergence of the quasispecies during the 
inapparent stage of disease. These increases occurred concurrently with maturation of the 
humoral immune response, suggesting that humoral immunity contributes to diversifying 
selection. 
Methods 
Experimental Infection 
The experimental infection of pony 524 was previously reported (18). The pony was 
infected with 103 horse infectious doses of virulent Wyoming strain of EIAV (EIAVWyo)-
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Sera and plasma were collected during clinical and subclinical infection (Figure I) and stored 
at -80°C until analyzed. 
Virus Neutralization Assay 
Virus neutralization assays were performed using equine dermal cells (ED) 
maintained in Dulbecco's modified eagle medium (DMEM) supplemented with fétal calf 
serum, penicillin, and streptomycin as previously described (5). Neutralizing antibody titers 
were assayed in sera samples from at least two different time points from each of the clinical 
stages of disease, and pre-inoculation serum was used as a negative control. Sera was heat 
inactivated to destroy complement, serially diluted two-fold in supplemented DMEM, and 
incubated at 37°C for 1 hr with 500 focus forming units (FFU) of the cell adapted 
EIAVwsu-s. Quadruplicate wells of ED cells were inoculated with the virus-serum mixture in 
the presence of 4 |ig polybrene, and the culture media was changed the following day. Cells 
were incubated for an additional 72 hours, fixed with ice cold methanol, and foci of EIAV-
infected cells were detected by immunocytochemistry. Foci of infected cells were counted 
and results were expressed as the serum neutralization titer, defined as the highest serum 
dilution that gives a 75% reduction in foci as compared with preimmune and negative control 
serum. 
RT-PCR amplification, cloning, and sequence analysis of viral genotypes 
Sera samples were collected throughout infection (Figure 1). To obtain viral RNA, 
200 pi of serum were centrifuged at 93,000 x g for one hour at 4° C. Viral RNA was isolated 
from the pellet by guanidine thiocyanate lysis and acid phenol-chloroform extraction using a 
commercially available kit (Ambion, Austin, TX). RNA was resuspended in 25 pi RNase-
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free glass distilled water containing 0.1 raM EOT A. Samples were DNase treated by adding 
two units of DNase I (Ambion, Austin, TX) to 3 pi of viral RNA, 20 mM MgCh, 1 mM of 
each dNTP, IX PGR buffer II (Perkin-Elmer, Branchburg, NJ), 20 units of RNase inhibitor, 
and 2.5 mM of random hexamers in a total volume of 20 pi. The reaction was incubated at 
37° C for 30 minutes and heated to 75° C for 5 minutes to inactivate the DNase. After 
cooling to 4° C, 50 units of Moloney murine leukemia virus reverse transcriptase were 
added. Reactions were incubated at 42° C for 45 minutes, heated to 99° C for 5 minutes, and 
then cooled to 5° C for 5 minutes. PGR reactions were brought up to 100 pi with 2 mM 
MgCh, 0.2 mM of each dNTP, IX PGR buffer U, 2.5 units of Taq polymerase, and I pM of 
each primer. PGR amplification conditions were 37 cycles of denaturation at 94° G for two 
minutes, annealing at 50° G for 1 minute, and extension at 72° G for 1 minute. The initial and 
final cycles contained a prolonged extension at 72° G for 5 minutes. Two regions of the env 
gene were amplified using primers chosen from conserved regions of SU as determined from 
EIAV env sequences available in GenBank data. The upstream region included the V2, V3, 
and V4 variable regions and was amplified with primer pair 1 (Table 1). The downstream 
region contained variable regions V5, V6, and V7 and was amplified with primer pair 2 
(Table 1). Two microliters of PGR product were ligated into pGEM-T vectors according to 
the manufacturer's recommendations and transformed into Escherichia coli DH-5a. Positive 
clones were identified by colony blot hybridization using a subgenomic fragment of env 
labeled with [32P]dTTP by random primed labeling (Roche Molecular Biochemical, 
Indianapolis, IN). Plasmids were isolated from positive clones and the env inserts were . 
sequenced bidirectionally with primers to vector sequences flanking the insert All 
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sequencing was performed by the Iowa State University DNA Synthesis and Sequencing 
Facility using an automated DNA sequencer. 
Amino acid alignment and analysis of diversity and divergence 
Each region was translated in the SU open reading frame, aligned, and analyzed using 
BioEdit 4.8.6 (8). Diversity and divergence calculations were performed on the amino acid 
sequences of each region for all pair-wise distances using a PAM250 matrix. The diversity of 
each time point is the pair-wise distances of all sequences at each particular time point while 
divergence is the pair-wise distances of each time point as compared to the consensus 
sequence of the inoculum. 
Results and Discussion 
Clinical profile of EIAVWyo-infected pony 524 
The experimental inoculation and clinical disease course in pony 524 was previously 
described (3). After inoculation, pony 524 experienced a clinical disease course characterized 
by recurrent fever cycles interspersed with afebrile periods ranging from days to months 
(Figure 1). The initial acute episode included a bi-phasic febrile response and 
thrombocytopenia from 10 to 22 days post infection (DPI), followed by a chronic period 
characterized by seven recurrent fever episodes, which ranged from two to six days in length. 
The last fever episode within the chronic period of disease occurred on day 135, and pony 
524 remained afebrile except for two late fever episodes at days 565 and 799. These two 
episodes were accompanied by thrombocytopenia and increased viremia, consistent with an 
EIAV etiology (3). Neutralizing antibody to the cell culture derived strain of EIAVwyo, 
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EIAVWSU-5 (17), appeared at the onset of the inapparent stage of disease (Figure 1) and was 
maintained throughout the remainder of infection. 
Quasispecies evolution in V2-V7 during disease progression 
Many studies have characterized the population of viral variants present during 
febrile episodes. Few, however, have examined genotypes present during the inapparent 
stage of disease. We and others have demonstrated that there is ongoing virus replication 
during the inapparent stage of disease (3,10). The disease course in pony 524 provided an 
opportunity to characterize changes in the env quasispecies at well-defined stages of disease, 
namely the acute, chronic, and inapparent stages. 
Inoculum. The inoculum was characterized by a heterogeneous population of amino 
acid (a.a.) variants. Of the 28 V2-V4 clones sequenced, 10 unique variants were identified 
(Figure 2). The predominant a.a. sequence in the inoculum, designated V2-4.1, represented 
32 percent of the clones and is referred to as the founder sequence. Analysis of 28 V5-V7 
clones identified 20 distinct amino acid variants, which varied predominantly in previously 
defined variable regions (Figure 3). The V5-V7 founder sequence, V5-7.1, represented only 
14.3 % of the amino acid variants from the inoculum, suggesting that no single variant was 
clearly dominant In both regions, variation occurred mainly in the previously identified 
variable regions (14). 
Acute. The quasispecies present during the acute period (12,35 dpi) was very similar 
to that found in the inoculum. Of the 26 V2-V4 clones that were sequenced, we observed 
nine different a. a. variants, four of which had been previously detected in the inoculum. 
Further, the novel variants differed by only one amino acid substitution relative to the 
founder sequence. Twenty six V5-V7 clones were obtained from the acute stage of disease. 
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Although there were few amino acid changes among all variants, only three variants had 
been previously detected in the inoculum. Again, the amino acid changes were largely 
confined to previously defined variable regions. 
Chronic. The chronic stage of disease was characterized by the emergence of novel 
genotypes resulting from point mutations primarily in the variable regions of SU. The most 
notable changes were those that altered size, charge, or putative N-linked glycosylation sites 
within V3. Variants that differed in size relative to the founder sequence, resulting from 
insertion or deletions of a.a. within V3, appeared at 89 and 118 dpi (V2-4.27, -28, and -34). 
Point mutations not only altered the amino acid identity among variants sequenced, but in 
some instances they also altered charge of the substituted amino acid. For example, H203Y 
and H204P substitutions occurred in several variants (67 and 118 dpi) conferring a net 
increase in positive charge. Genetic variation also altered the number and placement of 
putative N-linked glycosylation sites. At day 67, we observed novel variants that contained 
N184D substitutions frequently paired with a T186N substitution, consistent with gain of a 
putative N-linked glycosylation site (NXS/T). At 89 dpi both asparagines in V3 underwent 
substitution, most often with a serine (S200N and S210N). The S210N substitution 
eliminated a putative N-linked glycan. Atl 18 dpi, however, the N184D and T186N 
substitution was predominant among the variants. Other changes included premature stop 
codons between V3 and V4 in three of the variants at 67 dpi and a predominant V242L 
substitution at 118 dpi. V2-4.17 contained a large V3 motif previously detected in two 
independently derived tissue culture adapted biological clones (17,21). Compared with the 
founder sequence, it differed by deletion of the majority of the founder V3 motif, with 
insertion of another; V2-4.17 was not detected at subsequent time points. The extent of 
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variation in V3 was similar to that previously found (15), suggesting that these changes may 
result in antigenic changes and evasion of the host immune response. 
All V5-V7 variants detected during the chronic stage of disease were novel. 
Compared with the acute stage of disease, there was an increase in variation in V5 and V6. 
We observed an M2991 substitution predominant at 67 dpi, and a shift in a putative N-linked 
glycosylation site in V6 from 347 to 345 among most variants during the chronic stage. 
Additionally, an N341S substitution was present in four variants at 89 dpi, and in all variants 
at 118 dpi. Thus, changes in charge and putative N-glycan placement were the most notable 
differences among variants from the chronic stage of disease. Overall, the extent and location 
of genetic changes observed in pony 524 were similar to that previously reported in horses 
inoculated with biological or molecular clones (13-15,19). 
Inapparent The inapparent stage of disease (201,289,385,437 dpi) was 
characterized by a marked increase in genetic variation, predominantly due to insertions and 
deletions in V3. All a.a. variants from 201 dpi contained an insertion of two to four amino 
acids in V3 that, in most cases, resulted in gain of a putative N-linked glycosylation site. 
Most remarkably, there were several examples of deletion/insertion events within V3, with 
several different V3 amino acid insertion sequences detected. At 289 dpi, the predominant 
event was deletion of "NSFYPVNEST' and insertion of"SSYPQSWISPAPNFT". 
However, other deletion/insertion events were evident, as was a duplication event (V2-4.53). 
Similarly, deletion/insertion events occurred at 385 dpi which resulted in the appearance of 
several novel V3 amino acid motifs. Deletion/insertion events also occurred in all variants 
detected at 437 dpi. The predominant V3 insertion at 437 dpi contained a 
"DSPLGMTELDVIRHSSHGNWT" motif, and V2-4.55, which contained this motif, 
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represented more than half of the variants. The other variants' motif bore resemblance to 
previously detected variants at 289 and 385 dpi. Previous studies have described deletion or 
insertions from duplication of viral sequence in EIAV V3 (13,14,23). Here, however, the 
insertion/deletion events did not appear to arise from duplication events, but rather from 
deletion of an existing motif and insertion of a completely novel motif. 
Increased genetic variation was observed in V2 and V4 during the inapparent stage as 
well. At 201 dpi, a G253D substitution in V4 was predominant and there was also fixation of 
the contiguous M144I and Y145H co-substitutions in V2. At 289 dpi, V2 retained the M144I 
and Y145H co-substitutions predominant at 201 dpi, but also frequently contained an N143S 
substitution. V2 and V4 contained few novel sequence changes at 385 dpi. 
In V5-V7, for 201,289, and 385 dpi, each time point sampled only contained variants 
that had not been detected at earlier time points. Similarly, many of the variants present at 
437 dpi were novel, with the exception of V5-7.82, which first appeared at 385 dpi. The 
genetic variation among V5-V7 variants was mostly confined to variable regions; however, 
there was an increase in amino acid substitutions outside of the variable regions as well. 
Additionally, V7 contained insertions of one to four amino acids, with insertion of more 
amino acids occurring toward the end of the inapparent stage. Thus, while size variation in 
V3 appeared to contribute considerably to the observed genetic variation during the 
inapparent stage of disease, point mutations in all variable regions and limited size variation 
in V7 were also present 
Late febrile. The quasispecies at the late febrile episode was more homogeneous than 
that observed- during the inapparent carrier stage. However, the predominant V3 motif was 
very different than those previously observed, again indicating deletion of one motif and 
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insertion of another. Interestingly, the predominant amino acid sequence detected at day 800, 
V2-4.50, was previously detected at day 289, suggesting that this variant was present at low 
frequency during the inapparent stage of disease. There were no amino acid differences in 
V2; truncations of the region sequenced occurred among four of the twelve variants. Within 
V5-V7, genetic variation was predominantly confined to variable regions, with all but one of 
the variants being novel. A predominant feature of the V5-V7 variants at 800 dpi was size 
variation at the 3* region of V5. Nucleotide sequence analysis of the variants suggests that 
the insertions (9 or 13 amino acids in length) were generated by duplication events among 9 
variants (V5-7.95, -96, -97, -98, -101, -102), and duplication and recombination events in 
two variants (V5-7.99, -100) (Figure 4). Although size variation is well documented for V3, 
this is the first report of size variation in V5. Interestingly, the observed size variation in V5 
was contiguous with a region containing a neutralizing epitope (2). Finding size variation in 
both V3 and V5, where neutralizing epitopes have been mapped, suggests that size variation 
may be important in generation of genetic and antigenic variants for immune evasion. 
Calculation of diversity and divergence by stage of disease 
In order to determine if the stages of disease were under different selective pressures, 
diversity and divergence calculations were done using BioEdit 4.8.6 analysis on the amino 
acid sequences of each region. This program calculates all pair-wise distances using a 
PAM250 matrix. Due to difficulties in performing these calculations with regions of variable 
length, V3 region was eliminated from V2-V4 clones for these calculations. We grouped the 
genotypes by stage of disease: the chronic period included sequences from 67,89, and 118 
• DPI; the inapparent stage included sequences from 289,385, and 437 DPL This grouping 
eliminated stages with low sample size (acute and late febrile) as well as transition periods 
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(201 DPI). There was a 100% increase in diversity during the inapparent stage of disease 
relative to the chronic stage in both V2-V4AV3 and V5-V7 (Figure 5). These results are 
consistent with diversifying selective pressure during the inapparent stage of disease. The 
two-fold difference in diversity between V2-V4AV3 and V5-V7 is likely due, in part, to 
absence of V3. Although we did not calculate the diversity for the late fébrile period 800 dpi, 
it was apparent from the sequence alignments that the degree of heterogeneity in the V2-V4 
and V5-V7 populations was similar to that observed during the acute and chronic periods. 
These findings suggest that clinical disease is associated with lower viral diversity. 
Interestingly, in pony 524, development of broadly reactive neutralizing antibodies occurred 
concomitant with onset of the inapparent stage of disease (3). Maturation of the humoral 
immune response (9-11) is characterized by an increased affinity and avidity of the antibody 
response. Similarly, there is a broadening of the neutralizing antibody response that 
characterizes chronic HTV-l infection, the stage that precedes development of acquired 
immunodeficiency syndrome (AIDS) (22). Maturation of the humoral immune response may 
contribute to diversifying selection of viral variants. Interestingly, however, the increase in 
diversity was not accompanied by recrudescence of disease, as might be expected if immune 
escape were the only selective factor. Indeed, it is likely that other factors contribute to the 
diversification of the quasispecies during the inapparent stage of disease. 
There was a 100 percent increase in divergence during the inapparent stage of disease 
compared to the chronic stage in V2-V4AV3 and V5-V7 (Figure 5). The two-fold increase in 
divergence between V2-V4AV3 and V5-V7 is, once again, likely due to elimination of V3 
from the calculation. Notwithstanding, the increase in divergence from the chronic stage of 
disease to the inapparent stage of disease indicated ongoing evolution of the quasispecies 
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between these defined stages of disease. Our results suggest ongoing diversifying selection 
during the inapparent stage of disease, and support the notion of a mature humoral immune 
response as being a key contributing factor in diversification of the quasispecies. 
Detection of V3 motifs in the inoculum 
Previous studies have identified insertion/deletions within the V3 region of EIAV 
envelope (13,14,19,23). In some cases, these are thought to be due to duplication events 
(13,14,23); in other cases the origin of the insertions is not readily evident (19). This raised 
the possibility that the insertions do not evolve in pony 524, but pre-exist at a low frequency 
in the inoculum. For example, the predominant V3 motif at 437 dpi is not present elsewhere 
in the EIAV genome, and did not appear to arise by duplication events. We therefore sought 
to determine if the inoculum contained variants with this motif. The insertion was sufficiently 
large for primer design, facilitating semi-nested RT-PCR. Primer pair 3 (Table 1) was used 
for primary RT-PCR amplification across V3. Primer pairs 4 and 5 were used in semi-nested 
reactions using the primer pair 3 RT-PCR reaction product as template. The conditions used 
were as previously described, with the semi-nested PCR reaction run for 25 cycles. 
Using this technique, we were able to retrieve variants from the inoculum containing the 
motif which predominated at 437 dpi (Figure 6). This indicates pre-existence of this motif in 
the inoculum and its emergence as a predominant motif during the inapparent carrier stage of 
disease. The predominance of the 437 dpi V3 motif during the inapparent stage of disease 
may be due to differences in relative fitness of437 dpi V3 motif containing variants vis-à-vis 
a changing selective environment. Indeed, it is possible that the observed maturation of the 
humoral immune response selects for V3 variants with resistance to neutralizing antibody. 
Therefore, our data are consistent with both a wild-type inoculum composed of a 
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quasispecies with variants variably suited for different stages of disease and de novo 
generation of viral variants during infection. 
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Table 1. Primer pairs used for amplification of EIAV SU sequences 
Primer pair Primer name1 Primer sequence (5'->3') 
1 CG 5673 
CG6112C 
AATGCTGGGGTTCCTTCC 
ACACAGCCTGATTGGATG 
2 CG 6029 
CG6469C 
CCTAAGGGGTGTAATGAG 
TGCCTGTCCTATAACTCC 
3 CG 5769 
CG 5962C 
ACTGCTACATTATTAGAAGCT 
TTCTGTTTGATTACATTCTAG 
4 CG 5769 
BS4934-PC 
ACTGCTACATTATTAGAAGCT 
ATGAGAGGAGTGCCGGATC 
5 BS4933-P 
CG 5962C 
GATTTTCAGGCAGACGCCCCACTTG 
TTCTGTTTGATTACATTCTAG 
'Primers arc numbered according to the nucleotide sequence of EIAV CG, GenBank accession number 323836 
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Figure 1. Clinical profile of Pony 524. Stages of disease are indicated at top of 
figure. Chronic stage is boxed. Fever episodes are indicated in columns on y-axis. 
Virus neutralizing antibody titer to EIAVwsu-s is indicated by red line. Date of 
serum samples from which viral RNA was isolated are indicated along x-axis. 
Figure 2, Alignment of V2-V4 SU amino acid sequences obtained from sera of pony 524 at 12,35,67,89,118,201, 
289,385,437,800 days post inoculation (DPI). The variant identity and number of clones are indicated at the left of 
the sequence. Dots (.) indicate an identical amino acid to the reference sequence, V2-V4.1, at that position. Hyphens 
(-) indicate gaps in the sequence. Asterisks (*) indicate a premature stop codon in the SU ORF. The contiguous 
epitopes for neutralizing antibody are underlined. The variable regions are boxed: variable region 2, V2; variable 
region 3, V3; variable region 4, V4. Stages of disease are indicated to the left of the alignment. Numbers in 
parentheses indicate the number of clones represented by that variant. Numbering at the top of the alignment is 
according to the start site of the SPEIAV19R SU ORF. 
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Figure 3. Alignment ofV5-V7 SU amino acid sequences obtained from sera of pony 524 at 12,35,67,89, 118,201,289, 
385,437,800 days post inoculation (DPI). The variant identity and number of clones are indicated at the left of the 
sequence. Dots (.) indicate an identical amino acid to the reference sequence, V5-V7.1, at that position. Hyphens (-) 
indicate gaps in the sequence. Asterisks (*) indicate a premature stop codon in the SU ORF. The epitope for neutralizing 
antibody in V5 is underlined. The variable regions are boxed: variable region 5, V5; variable region 6, V6; variable region 
7, V7. Stages of disease are indicated to the left of the alignment. Numbering at the top of the alignment of the SU ORF 
continues from figure 2. 
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Figure 4. A proposed model of recombination and duplication of nucleic acid for generation of 
size variants in V5 at 800 dpi. Clones ID-l, 385D-5,800D-24, and 800D-18, when translated 
into the SU open reading frame, are the amino acid variants V5-7.1, V5-7.88, V5-7.95, and V5-
7.99, respectively. Hyphens indicate gaps in the alignment. Proposed regions of duplicated 
nucleic acid are boxed with regions of homology in the same color; the pattern is indicated at 
the bottom of the alignment. 
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Figure 5. Divergence and diversity of populations during different stages of clinical disease. 
(A) Divergence is calculated as all the pair-wise comparisons from one time point to the 
consensus sequence of the inoculum corrected with a PAM250 matrix. The chronic period is 
represented by open bars and the inapparent is filled with black. (B) Diversity is calculated 
by all pair-wise comparisons of the amino acid sequences at one time point corrected with a 
PAM250 matrix. The chronic period is represented by open bars and the inapparent is filled 
with black. 
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Figure 6. Detection of day 437 V3 motifs in EIAVw>o2078 inoculum. Clones were obtained from semi-nested PCR reactions of the 
inoculum, sequenced, and translated into the SU open reading frame. The predominant clone of the inoculum, V2-4.1, is used as a 
reference sequence. Dots indicate identical amino acid identity; hyphens indicate gaps in sequence. Eleven clones were identical in 
sequence to that of the inoculum. Four clones were identical to the predominant sequence at 437 dpi. The primer binding sites are 
underlined. 
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CHAPTER 3. EIAV VARIANTS THAT EMERGE LATE IN INFECTION 
RESIST BROADLY ACTIVE NEUTRALIZING ANTIBODY AND SHOW 
REDUCED REPLICATION IN VITRO 
To be submitted to Journal of Virology 
Brett A. Sponseller, Yvonne Wannemuehler, Yuxing Li, 
Amanda K. Johnson, and Susan Carpenter. 
Abstract 
The principal neutralizing domain (PND) of equine infectious anemia virus (EIAV) is 
located in the V3 region of the surface unit envelope glycoprotein (SU). Genetic and 
antigenic variation in the PND is considered to play an important role in EIAV persistence; 
however, few studies have characterized variants isolated during the inapparent stage of 
disease. We undertook a longitudinal study of SU variation in a pony experimentally 
inoculated with the virulent, wild-type, EIAVwyo- Viral RNA isolated from the inoculum and 
from sera collected sequentially during the acute, chronic, and inapparent stages of infection 
was amplified by RT-PCR, cloned, and individual clones were sequenced. Of the 147 SU 
clones obtained, we identified 84 distinct V3 variants that partitioned into five major groups, 
designated PND-I to PND-V. The groups segregated with specific stages of clinical disease 
such that PND-I was predominant in the inoculum and acute stage of infection; PND-H was 
Department ofVcterinary Microbiology and Preventive Medicine, Iowa State University 
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dominant during the chronic stage; PND-HI and -IV were found only in the inapparent stage; 
and PND-V predominanted during a late, febrile episode. Genotypes representative of each 
group were subcloned into the infectious pro viral clone pSPEIAV-19R, and sera from 
successive times post infection were tested for virus neutralizing antibody (VNAb) to 
chimeric virus stocks. High levels of type-specific neutralizing antibody to PND-I virus were 
detected early after infection and coincided with decline of the PND-I genotype, suggesting 
that VN antibody contributes to resolution of acute EIA disease. However, we did not 
observe a sequential appearance of type-specific antibody to PND-0, -HI ,-IV, and -V 
viruses. Rather, VNAb to the PND-0, -HI, and -IV viruses coincided with the appearance of 
antibody to SPELAV-19R virus. While PND-I was clearly antigenically distinct, there were 
no significant antigenic differences among PND-0, -ID, and -IV viruses. High titered 
neutralizing antibody did not develop to PND-V, suggesting that this genotype conferred 
resistance to neutralization. The replication phenotype of the chimeric viruses was assayed in 
monocyte-derived horse macrophage cultures (MDM) and equine dermis cells (ED). All 
viruses replicated to higher titers in ED cells than MDM. However, PND-V replicated to 
lower titer in both MDM and ED. Together, these results suggest that cross-neutralizing 
antibody develops during the inapparent stage of disease, that variants acquire resistance to 
type- and group-specific neutralizing antibody as disease progresses, and that resistance to 
neutralization may be accompanied with decreased fitness for replication. 
Introduction 
Equine infectious anemia virus (EIAV) is a member of the Lentivirus subfamily of 
retroviruses. Similar to other lentiviruses, EIAV has a complex genome organization, a 
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tropism for cells of the monocyte/macrophage lineage, and can establish lifelong persistence 
in the host However, in contrast with most lentiviruses, EIAV may cause a rapid onset of 
disease characterized by recurrent episodes of viremia, fever, and thrombocytopenia 
(9,28,32,35,36). Interspersed among episodes of clinical disease are quiescent periods during 
which no signs of disease are evident, and viremia decreases. Anemia and dependent edema 
may develop in horses which experience several episodes of disease (32). Many horses 
survive the clinical episodes, which can recur for several months, and become inapparent 
carriers of the virus. Inapparent carriers are able to control virus replication; however, virus is 
not eliminated (8). Therefore, the EIAV lenti viral model provides an opportunity to study 
genetic and antigenic variation, well recognized mechanisms of lenti viral persistence, in a 
host that attains immunological control of the virus. 
Studies have characterized the progressive maturation of immune responses during 
EIA disease progression (11-13). hi particular, Hammond et al. observed that the humoral 
immune response required six to ten months to mature during which time EIAV-specific 
antibody progressed from a low-avidity, nonneutralizing, predominantly linear epitope 
specificity to one of high-avidity, neutralizing, predominantly conformational-epitope 
specificity (11). EIAV cytotoxic T lymphocyte (CTL) activity appeared within one month of 
infection and was temporally correlated with decline in initial viremia (11,22). However, 
later episodes of viremia did not appear to be controlled by CTL. In fact, loss of EIAV-
specific in vitro T-cell proliferative or cytolytic activity did not correlate with recrudescence 
of viremia and disease (11). Similarly, there was no correlation between clinical course and 
virus neutralizing antibody titers. Thus, it is unclear what the specific immune responses 
associated with control of virus load are as no specific correlates have been defined (11,12). 
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Recently, we and others have observed that inapparent carriers frequently maintain 
elevated levels of viremia (2,12), suggesting that many horses attain a set point of virus 
replication with immunologic control. To date, few studies have characterized the viral 
genotypes and phenotypes associated with the inapparent stage of disease. Without such 
studies, our understanding of the host-virus interactions occurring during inapparent disease 
remains incomplete. 
Several studies have described the development and presence of antigenic variants 
(16,25,26,31) while others have characterized genetic variation in the surface unit envelope 
glycoprotein (SU)(18-20,24,40) during episodes of clinical disease. However, a causal link 
between immune selective pressure and genetic variants is lacking, leaving many to speculate 
that genetic variation is the result of stochastic events (17,30). 
Variation in EIAV SU occurs predominantly in 8 hypervariable domains, V1-V8 
(18,19). The EIAV V3 hypervariable region has been proposed to contain a loop, anchored 
by two cysteine residues. Using cell adapted virus, this region was previously shown to 
contain two epitopes recognized by neutralizing mouse monoclonal antibodies and has been 
termed the principal neutralizing domain (PND) (1,19,24,41). The localization of an 
immunodominant variable region in SU suggests that this region would be important in 
mediating immune escape from neutralizing antibody. Recently, Howe et al. demonstrated 
that variation in the V3-V4 regions results in an increasingly resistant neutralization 
phenotype during disease progression (14). However, that study did not assess V3-V4 
variation on neutralization phenotype during the inapparent stage. In fact, to date no studies 
have examined the neutralization phenotypes of viral variants present during both clinical 
and inapparent stages of disease. Without such studies it is not possible to appreciate the 
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dynamic interaction of the viral quasispecies and the host immune response that ultimately 
results in immune control of virus replication. 
In the present study, we undertook a series of experiments to analyze the 
neutralization phenotype of viral variants present at acute, chronic, and inapparent stages of 
disease in a single, experimentally infected pony. Consistent with previous findings, 
antigenic variants were detected at different stages of disease. To assess neutralization 
phenotype, predominant genotypes were inserted into the context of an infectious molecular 
clone. Significantly, the predominant genotype from the acute stage of disease was 
neutralized by type-specific antibody whereas the predominant genotypes from the chronic 
and inapparent stages of disease were neutralized by broadly reactive, cross neutralizing 
antibodies. A late febrile episode provided the opportunity to examine the neutralization 
phenotype of a variant associated with recrudescence of disease. That variant was resistant to 
neutralization by VNAb and had a lower replication capacity in vitro compared with the 
backbone and chimeric viruses. 
Materials and Methods 
Experimental infection 
The experimental infection of pony 524 was previously reported (23). The pony was 
infected with 103 horse infectious doses of virulent Wyoming strain of EIAV (EIAVw>o). 
Sera and plasma were collected during clinical and subclinical infection (Figure I) and stored 
at -80* C until analyzed. 
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RT-PCR amplification and cloning 
A 440 nucleotide region of the env gene was amplified from viral RNA using 
primers designed to conserved regions of the envelope as determined from EIAV env 
sequences available GenBank data. Primers were named according the EIAV CG nucloetide 
sequnce number (39), and had the following sequence: upstream: CG5673 AATGCTGG 
GGTTCCTTCC; downstream: CG6112C' ACACAGCCTGATTGGATG. To obtain viral 
RNA, 200 (il of serum from the experimentally infected pony were centrifuged at 93,000 x g 
for one hour at 4° C. Viral RNA was isolated from the pellet by guanidine thiocyanate lysis 
and acid phenol-chloroform extraction using a commercially available kit (Ambion, Austin, 
TX). The RNA was then resuspended in 25 gl RNase-free glass distilled water containing 
0.1 mM EDTA. Samples were DNase treated by adding two units of DNase I (Ambion, 
Austin, TX) to 3 |il of viral RNA, 20 mM MgCh, 1 mM of each dNTP, IX PGR buffer II 
(Perkin-Elmer, Branchburg, NJ), 20 units of RNase inhibitor, and 2.5 mM of random 
hexamers in a total volume of 20 gl. The reaction was incubated at 37° C for 30 minutes and 
heated to 75° C for 5 minutes to inactivate the DNase. After cooling to 4° C, 50 units of 
Moloney murine leukemia virus reverse transcriptase were added. Reactions were incubated 
at 42° C for 45 minutes, heated to 99° C for 5 minutes, and then cooled to 5° C for 5 minutes. 
Reactions were then brought up to 100 pi with 2 mM MgClz, 0.2 mM of each dNTP, IX 
PGR buffer II, 2.5 units of Taq polymerase, and 1 pM of each primer. PGR amplification 
conditions were 37 cycles of denaturation at 94° C for two minutes, annealing at 50° C for 1 
minute, and extension at 72° G for 1 minute. The initial and final cycles contained a 
prolonged extension at 72° C for 5 minutes. Two microliters ofPCR product were ligated 
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into pGEM-T vectors according to the manufacturer's recommendations (Promega 
Corporation, Madison, Wi) and transformed into Escherichia coli DH-Sa. Positive clones 
were identified by colony blot hybridization using a subgenomic fragment of env labeled 
with [32P]dTTP by random primed labeling (Roche Molecular Biochemical, Indianapolis, 
IN). Plasmids were isolated ftom positive clones and the env inserts were sequenced 
bidirectionally with primers to vector sequences flanking the insert. All sequencing was 
performed by the Iowa State University DNA Synthesis and Sequencing Facility using an 
automated DNA sequencer. Sequences were aligned by Mac Vector and AssemblyLIGN 
software (Oxford Molecular, Beaverton, OR). 
Generation of chimeric viruses containing representative wild-type genotypes 
Our data set of 147 SU clones containing V2-V4 (34) was translated into the SU open 
reading frame and aligned. Based on V3 amino acid similarity, 126 clones segregated into 
seven groups; twenty-one clones were unable to be grouped. Major groups contained greater 
than 80% of the clones at a given sampling time point whereas minor groups contained fewer 
than 55%. Selection of representative motifs for construction of chimeric viruses was based 
upon the consensus V3 amino acid sequence for each of the five major groups. To assure 
distinct grouping of amino acid variants, measures of genetic diversity and divergence were 
calculated. The genetic diversity of each group was estimated in terms of per-nucleotide 
expected heterozygosity, or nucleotide diversity within the V3 subregion of V2-V4. Two 
estimates of nucleotide diversity were calculated using DnaSP version 3.51,0 and it. 
Between group divergence was measured as the average number of nucleotide substitutions 
per site between groups, D*y. Plasmids containing the representative env genotype for each 
major group were digested with Sph 1ZBsu 361, and the SU fragment containing the variant 
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sequence was transferred through two shuttle vectors to reconstitute a full length chimeric 
pro viral clone containing the SphI to Bsu36I wild-type subregion. The backbone molecular 
clone used for these manipulations was pSPEIAV!9R. Plasmids containing chimeric env 
were verified by nucleotide sequencing and were co-trans fected into Cf2Th cells with 
pSVSNeo using liposome-mediated transaction (TransIT®-LT, Minis, Madison, WT). 
Transitants were selected in G418, and resistant cell clones were expanded in 24-well 
tissue culture plates and assayed for virus production using a reverse transcriptase (RT) assay 
(6). RT-positive clones were expanded for production of virus stocks, and stocks were 
aliquoted and stored at -70°C. Stocks were titered using a focal immunoassay which employs 
a chromogenic method of detection (5,33). 
Cell lines 
Equine dermis cells (ED, ATCC CCL 57) and canine fibroblast cells (Cf2th, ATCC 
CRL 1430) were maintained in Dulbecco's modified Eagles medium (DMEM) supplemented 
with antibiotics and fetal calf serum. Monocyte derived macrophage cultures (MDMC) were 
established as we previously described (27,33). Briefly, whole blood was obtained from 
EIAV-free horses by jugular venipuncture. Mononuclear leukocytes were banded by 
centrifugation at 750 x g on a discontinuous histopaque gradient, resuspended in Dulbecco's 
MEM (DMEM) containing 20% horse serum and 10% newborn calf serum (NCS), and 
seeded at 2 x 107 cells/cm2 in 24 well tissue culture plates. Monocytes were allowed to 
adhere overnight at 37°C and nonadherent cells were removed from the cultures by washing 
twice with Hank's buffered saline solution (HBSS) containing 2% fetal calf serum (ECS). 
Cells were maintained in DMEM containing 20% horse serum, 10% NCS and antibiotics. 
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Virus neutralization assays 
Virus neutralization assays were performed using equine dermal (ED) cells (6). 
Neutralizing antibody titers were determined using sera samples collected from Pony 524 at 
sequential time points from each of the clinical stages of disease. Pre-inoculation serum was 
used as a negative control. Sera was heat inactivated to destroy complement, serially diluted 
two-fold in supplemented DMEM, and incubated at 37°C for 1 hr with 550 focus forming 
units (FPU) of the chimeric virus. Quadruplicate wells of ED cells were inoculated with the 
virus-serum mixture in the presence of 4 gg polybrene, and the culture media was changed 
the following day. Cells were incubated for an additional 72 hours, fixed with ice cold 
methanol, and foci of EIAV-infected cells were detected by inununocytochemistry (5). Foci 
of infected cells were counted and results were expressed as the serum neutralization titer, 
defined as the highest serum dilution that gave a 75% reduction in foci as compared with 
preimmune and negative control serum. 
Characterization of virus replication 
Stocks of chimeric virus were assayed for RT activity and equivalent RT counts were 
inoculated in triplicate onto ED and MDM. The cells were washed and media replaced the 
day after inoculation. Supernatant was collected following the media change and every two 
days for a two week period. Supernatants were assayed for virus RT-activity, expressed as 
cpm/gl supernatant (6). 
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Results 
Clinical profile of EIAVwyo-infected Pony 524 
The experimental inoculation and clinical disease course in Pony 524 was previously 
described (2). After inoculation, pony 524 experienced a clinical disease course characterized 
by recurring fever cycles interspersed with afebrile periods ranging from days to months 
(Figure 1). The initial acute episode included a bi-phasic febrile response and 
thrombocytopenia from 10 to 22 days post infection (DPI), followed by a chronic period of 
seven recurrent fever episodes which ranged from two to six days in length. The last fever 
episode ended after day 135, and pony 524 remained afebrile except for two late fever 
episodes at days 565 and 799. These two episodes were accompanied with thrombocytopenia 
and increased viremia, consistent with disease caused by EIAV. 
Genetic variation during progression of disease 
Characterization of the V2-V4 quasispecies present during the clinical and inapparent 
stages of infection of Pony 524 has been previously described (34). In that study we observed 
a 100 percent increase in both the genetic diversity and divergence in the quasispecies with 
progression to the inapparent stage of disease, suggesting diversifying selection by virus 
neutralizing antibody. The inoculum and virus isolated from the animal at acute and chronic 
stages of disease were composed of a homogeneous quasispecies with differences among 
amino acid variants due primarily to point mutations. The quasispecies from the inapparent 
stage of disease was highly diverse, with much of this diversity due to en bloc 
deletion/insertion events in V3 and an increase in variation in both V2 and V4. The 
quasispecies from a late febrile episode was more homogeneous than that observed during 
the inapparent carrier stage. However, the predominant V3 motif was very different than 
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those previously observed, again indicating deletion of one motif and insertion of another. To 
examine the contribution of virus neutralizing antibody in disease progression, selection of 
variant virus, and maintenance of the inapparent stage of disease, a panel of representative 
chimeric viruses was evaluated for neutralization and replication phenotypes. 
Analysis of representative genotypes 
To identify representative genotypes for immunological and biological analyses, the 
entire V3 data set was aligned and grouped according to amino acid similarity. A total of 
126 of 147 clones could be placed into seven groups (Table 1) with twenty-one outliers that 
could not be grouped. Five of the groups contained 12 or more variants and represented 78% 
of the total population. Two minor groups each contained six or fewer variants. The genetic 
diversity within each group was estimated in terms of per-nucleotide expected 
heterozygosity, or nucleotide diversity within the V3 subregion of V2-V4. Two estimates of 
nucleotide diversity were calculated using DnaSP version 3.51, it and 6. Pi is the expected 
proportion ofpairwise differences per nucleotide site and is often referred to as nucleotide 
diversity. Theta measures the genetic variation as the expected proportion of segregating 
sites, a calculation that incorporates the mutation rate at each site. Both estimates of 
diversity were below 4% for each of the seven groups, but were nearly 20% for the outliers. 
This indicated a high degree of similarity within each group. Between group divergence was 
measured as the average number of nucleotide substitutions per site between groups, Dxy. 
Overall, the divergence observed between the groups was greater than the within group 
diversity, and increased over time. Thus, the groupings were supported by the low within-
group diversity coupled with greater divergence. 
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During progression of disease, there was a change in predominance of the V3 groups 
that correlated with changes in stage of disease. Group I was predominant in the inoculum 
and during the acute stage of disease while Groups II and VI were predominant during the 
chronic stage of disease. Group HI was predominant in early in the inapparent stage of 
disease. Although this was the most diverse group (Figure 2), all variants included in Group 
HI had 2-4 amino acid insertions in the same region of V3. Groups IV and VU were 
predominant during the inapparent stage of disease. 
To evaluate the phenotypes of each group, variants within each of the five major 
groups were aligned and the V3 consensus sequence was determined for each group (Figure 
3). A clone containing the V3 consensus sequence for each of Groups I to V was used to 
generate chimeric infectious clones in the pSPEAIV-l9R backbone (37). The overall strategy 
for construction of the clones containing variant SU sequences was to insert the SphVBsu36I 
fragment of a representative variant into the pro viral backbone to yield the complete, 
chimeric infectious clone (Figure 4). To generate infectious virus, plasmid DNA was co-
trans fected into Cf2Th cells with pSVSNeo and G418 resistant cell clones were expanded for 
production of virus stocks. 
Representative genotypes differ in susceptibility to virus neutralizing antibody 
Antigenic variation is an important strategy of immune evasion and lentivirus 
persistence. To examine whether the genetic differences in V3-V4 altered susceptibility to 
neutralization by Pony 524 serum, the five chimeric viruses were used in focal reduction 
assays against serum collected before, during, and after the appearance of the PND genotype. 
. Low titered neutralizing antibody to the backbone virus, SPEIAV19R, was first detected at 
201 dpi, increased to a titer of 64 at 289 dpi, and remained high at all subsequent time points. 
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The development of neutralizing antibody to SPEIAV19R was similar to that previously 
observed for EIAVwsu-s, with high titer virus neutralizing antibody coinciding with onset of 
the inapparent carrier stage of disease. This response likely represents the presence of 
broadly reactive, cross neutralizing antibodies that occur with onset of the inapparent carrier 
stage of disease ( 11 -13). 
Virus neutralizing antibody to PND-I was first detected at 67 dpi, and rapidly 
increased to a titer of 128 by 89 dpi. Subsequent Pony 524 serum samples were able to 
neutralize PND-I at the same or higher titer. Therefore, the VNAb response to PND-I 
differed from the response to SPEIAV19R in both the time of onset and rate of development, 
indicating that PND-I is antigenically distinct from SPEIAV19R. Interestingly, the 
appearance of high titered type-specific VNAb to PND-I was temporally correlated with the 
decline of the PND-I genotype (Figure 5 and Table I). This is the first evidence that 
neutralizing antibody may contribute to resolution of the acute stage of EIAV infection. 
There did not appear to be an effective type-specific neutralizing antibody response to 
PND-H or PND-m. Virus neutralizing antibody to PND-H was not detected until 201 dpi, 
and achieved a maximum titer of 64 at 289 dpi. In contrast to the VNAb response to PND-I, 
there was not a temporal increase in titer associated with the appearance and decline of the 
PND-H sequence motif. In fact, the PND-H genotypic motif persisted beyond development of 
neutralizing antibody to PND-H and was found as late as 385 dpi (Table 1). The pattern of 
development of VNAb to PND-H was essentially the same as that to SPEIAV19R, with small 
differences in titer within experimental error. These results suggest that PND-H and 
SPEIAV19R were neutralized by antibodies of similar specificity. Therefore, while we could 
not rule out presence of a type-specific response to PND-H, we would have expected type-
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specific antibody to be found in earlier serum samples, to neutralize to higher titer, and to be 
associated with decline of the group-II genotype. Together, this suggested absence of high 
titered, type-specific VNAb to PND-IL Similarly, VNAb to PND-III was first detected in 
serum from 201 dpi. Development of neutralizing antibody arose in a pattern similar to that 
of SPEIAV19R and PND-H, suggesting neutralization by broadly reactive antibodies. 
The development of neutralizing antibody to PND-IV was delayed compared with 
SPEIAV19R, PND-H, and PND-III, with onset of neutralization 88 days later, suggesting 
PND-IV was more resistant to neutralization than PND-I, -H, and -HI. The temporal 
dissociation between development of VNAb and predominance of the PND-IV genotype was 
even more notable. Virus neutralizing antibody to PND-IV was first detected at 289 dpi, prior 
to the appearance and predominance of the PND-IV genotype at 385 and 437 dpi, 
respectively (Figure 5 and Table 1). Increased resistance to neutralization is supported by 
predominance of the PND-IV genotype in the face of neutralizing antibody. 
In contrast to other variants, PND-V was clearly more resistant to neutralization as 
only a low titer of VNAb was detected at 289,385,498,567, and 677 dpi. Therefore, PND-
V was poorly neutralized by broadly reactive, cross neutralizing antibody that was effective 
in neutralizing earlier genotypes. This extends the recent finding of Howe et al. that SU 
variation during disease progression can result in increasing envelope neutralization 
resistance (14). Interestingly, the PND-V genotype was detected once at 289 dpi early during 
the inapparent stage of disease. It is possible that the PND-V genotype existed as a minor 
population throughout the intervening period of289 dpi to 800 dpi, becoming predominant at 
800 dpi. The emergence of PND-V at such a late stage of disease may be a result of 
98 
increased resistance to neutralization, suggesting that changes in the PND motif can mask 
recognition of cross neutralizing epitopes. 
The low neutralization titers obtained with pony 524 serum against PND-V could be 
due to host immune exhaustion or inherent resistance to VNAb. Therefore, we tested the 
neutralizing phenotype of chimeric viruses against heterologous wild-type sera containing 
high titered, cross neutralizing antibodies (Table 3). The tissue culture adapted SPEIAV19R 
was more easily neutralized by both homologous and heterologous sera than the chimeric 
viruses containing the wild-type V3, a finding similar to that previously demonstrated with 
HIV cell-adapted viruses (4,15). PND-I, -HI, and -IV were neutralized by both homologous 
and heterologous serum, although heterologous serum neutralized at lower titers. In contrast, 
PND-V was clearly resistant to neutralization by Pony 524 serum (498 dpi) and heterologous, 
wild-type EATVMA-convalescent serum. These results indicate that genetic changes in the 
V2-V4 region of PND-V confer increased resistance to neutralization, presumably by 
masking or interfering with recognition of cross-neutralizing epitopes. Moreover, since the 
PND-V genotype was detected during recrudescence of disease at 800 dpi, evasion of VNAb 
may also play a role in development of clinical disease in the face of a mature humoral 
immune response. 
Variation in PND alters charge and putative N-Iinked glycosylation 
Previous studies have suggested that alterations in the number and placement of N-
glycans in SIV and HTV SU can change the exposure of epitopes to neutralizing antibody 
(3,7). It has also been suggested that location of charged amino acids can affect 
neutralization (10). Therefore, we plotted the putative N-linked glycosylation sites and 
distribution of charged amino acids of the V2-V4 subcloned regions of the five chimeric 
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viruses (Figure 6). Three putative N-linked glycosylation sites, all outside the PND, were 
conserved among the five chimeric viruses. In contrast, there was great variation in the 
number and placement of putative N-glycans within the PND. PND-I and PND-H differed 
by four amino acids, three of which were located in the PND. N184D and T186N 
substitutions resulted in a gain of a putative N-glycan in PND-H and loss of a negative 
charge; also, an H204P substitution resulted in gain of a positively charged amino acid within 
the center of the PND. There was, additionally, a V242L substitution between V3 and V4. 
Although the relative role of each of these changes in altering neutralization phenotype is 
unknown, these were the only differences between PND-I and PND-H. As such, it seems 
probable that one or more of these amino acid differences contributed to PND-H escape from 
the type-specific antibody that was effective in neutralizing PND-I. The V3 of these chimeric 
viruses contained large, distinct insertions, making comparison among them difficult. 
However, there was a general trend for the wild-type PND motifs detected at later stages of 
disease to contain a higher net negative charge, which has been suggested to enhance 
resistance to neutralization (10). 
Representative genotypes differ in kinetics of replication in vitro 
In HTV-l infection, progression to AIDS is associated with changes in V3 that alter 
cell tropism. Few studies have examined the relative contribution, if any, of the ELAV SU in 
determination of cell tropism. Therefore, the five chimeric viruses were tested for replication 
efficiency in equine dermis (ED) cells and monocyte-derived macrophage (MDM) cultures. 
Virus stocks were normalized for reverse transcriptase (RT) activity and inoculated in 
triplicate onto both ED cells and MDM. Supernatant was collected at varying time post 
inoculation and assayed for virion RT-activity. All viruses replicated to higher titer in ED 
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cells compared to MDM, indicating the wild-type V2-V4 motifs did not alter cell tropism in 
the SPEIAV19R context (Figure 7). In both cell types, however, PND-V replicated more 
slowly and achieved a lower titer than SPEIAV19R and the other four chimeric viruses 
(Figures 8 and 9). This suggested that genetic variation in the PND-V V3-V4 may influence 
the kinetics of virus replication. Thus, the PND-V phenotype showed increased resistance to 
neutralization, replicated more slowly, and achieved a lower titer. Therefore, SU variants that 
persist have clear differences in in vitro replication and neutralization phenotypes when 
compared with variants from earlier stages of disease. 
Discussion 
We performed a genotypic and phenotypic analysis of EIAV SU variants during 
disease progression in an experimentally infected horse. Using infectious chimeric viruses, 
an assessment of in vitro replication phenotype and neutralization phenotype of predominant 
V2-V4 SU variants indicated that acute disease is accompanied by high-titered type-specific 
neutralizing antibody; that cross-neutralizing antibody develops during the inapparent stage 
of disease; that variants acquire resistance to type- and group-specific neutralizing antibody 
as disease progresses; and that resistance to neutralization may be accompanied with 
decreased fitness for replication. 
The progressive maturation of immune responses during EIA disease progression has 
been well characterized (11-13). Resolution of early episodes of viremia correlates with 
EIAV cytotoxic T lymphocyte (CTL) activity (11,22) while maintenance of the inapparent 
stage of disease coincides with development of high-avidity, neutralising, predominantly 
conformational-epitope specific antibody (11,12). Despite the use of many different assays of 
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immune function, the specific immune responses associated with control of virus load are 
unclear and no specific correlate of immunologic control has been defined (11,12). Indeed, 
the recent finding that there is ongoing virus replication during the inapparent stage of 
disease, sometimes at levels attained during clinical disease, suggests that there is 
establishment of a set point of virus load at which the horse can maintain immunologic 
control. Further, it is clear that immunologic control does not equate with strict suppression 
of virus replication. To date, few studies have examined EIAV SU genotypes present during 
the inapparent stage of disease and none has reported a phenotypic characterization of viral 
variants present during the inapparent stage of disease. Thus, our understanding of the host-
virus interactions that occur during immunologic control and inapparent disease is 
incomplete. 
Previous studies demonstrated that CTL activity can control lentivirus replication and 
that such activity correlated with resolution of initial viremia (11,22). In contrast, 
development of VNAb did not occur until after resolution of acute disease (6,29). Therefore, 
the general understanding of immune control of acute EIA is that CTL are the primary 
effectors in limiting virus replication. Our results suggest that VNAb also contributes to 
control of initial viremia, as PND-I, representative of the predominant acute genotype, was 
effectively neutralized by type-specific antibody. Moreover, there was a decline in the PND-
I-genotype with development of type-specific antibody. These results indicate that type-
specific neutralizing antibody can contribute to resolution of acute disease. 
Studies have characterized qualitative and quantitative differences in EIAV-specific 
antibody during progression of disease from antibody with low-avidity, nonneutralizing, with 
predominantly linear-epitope specificity to one of high-avidity, neutralizing, predominantly 
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conformational-epitope specificity (11). Our results extend those findings and suggest that 
over time there are qualitative differences in the epitopes recognized by VNAb. Our 
observation that SPEIAV19R, PND-H, and m were neutralized at the same time and to 
similar titer suggests that these viruses were neutralized by broadly reacting, cross 
neutralizing antibody. Further, these results suggest that these viruses contained common 
epitopes. When considered together with the VNAb results for PND-I, our results indicate 
that type-specific antibody can develop early in disease and can rapidly select for escape 
mutants, such as PND-H. Further, recognition of cross reactive epitopes requires humoral 
immune maturation and results in neutralization of variants during the chronic and early-
inapparent stages of disease. 
Our results indicate that variants acquire increasing resistance to neutralizing 
antibody as disease progresses and extend the findings of Howe et al. who detected increased 
resistance to neutralization by V3-V4 EIAV variants with disease progression (14). In that 
study, virus chimeras were made from variants predominant during febrile episodes. Our 
findings suggest that selection of variants resistant to neutralization occurs during inapparent 
disease, too. Moreover, it would appear that selection of resistant variants is more a function 
of time, rather than stage of disease, possibly due to ongoing maturation of the humoral 
response. Indeed, the PND-V genotype was detected during recrudescence of disease at 800 
dpi, suggesting that evasion of VNAb plays a role in development of clinical disease in the 
face of a mature humoral immune response. 
Interestingly, the viral genotype with the greatest resistance to VNAb showed reduced 
replication in ED and MDM. At this time, it is not clear if variants with reduced replication 
efficiency are selected independently of neutralization phenotype, or if the replication 
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phenotype is a consequence of neutralization resistance. Nonetheless, our results suggest that 
the neutralization phenotype for PND-V is robust enough to offset any ill effect of decreased 
relative replicative capacity since this genotype clearly predominated at 800 dpi during an 
episode of disease recrudescence. Recent models using computer generated digital organisms 
with mutation rates similar to those of lend viruses have examined the quasispecies theory 
vis-à-vis replication over time (38). These studies indicated that displacement of a fast 
replicator by a more robust, slower replicator is possible depending on changes in the fitness 
landscape (environment). Perhaps the neutralization resistance phenotype of PND-V in a 
mature immune environment was sufficient to compensate for its decreased in vitro 
replication capacity. 
Recent findings in HTV indicate that there can be a correlation between replication 
fitness in culture and viral load in vivo, and that patients who are long-term survivors tend to 
be infected with viruses that are intrinsically less fit in culture (21). These findings suggest 
that the in vitro differences in replication we detected for the chimeric viruses can reflect 
replication phenotype in vivo. For EIAV, previous studies using chimeric viruses have not 
detected significant differences in maximum titer achieved by V3-V4 chimeric viruses in 
vitro unless variable regions were interchanged from different days post inoculation (14). 
Our virus chimeras contained V3 and V4 domains from the same clone, suggesting that these 
regions should be compatible for replication. Thus, it is possible that the PND-V, wild-type 
V2-V4 sequence introduced into the cell adapted backbone imposed replication constraints, 
such as interference with efficiency of receptor binding due to altered SU structure, and may 
reflect decreased replicative capacity in vivo. Considered together, the trade-off of decreased 
replication capacity for increased resistance to neutralization appears to be favorable for 
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variants that persist during EIAV infection. Our results suggest that EIAV variants resistant 
to serum neutralization arise during the course of persistent infection and may influence 
progression of disease. 
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Table 1. V2-V4 variants grouped according to V3 motif 
Group* 
Stag*6 DPI6 I II III IV V VI VII Outliers" Total 
Inoculum 27* 0 0 0 0 0 0 2 29 
Acute 12 12 0 0 0 0 0 0 0 12 
35 13 0 0 0 0 0 0 0 13 
Chronic 67 3 5 0 0 0 0 0 4 12 
89 0 2 0 0 0 6 0 3 11 
118 0 10 1 0 0 0 0 0 11 
Inapparent 201 0 0 11 0 0 0 0 0 11 
289 0 0 0 0 1 0 5 5 11 
385 1 4 0 3 0 0 0 5 13 
437 0 0 0 10 0 0 0 2 12 
Late febrile 800 0 0 0 0 12 0 0 0 12 
Total 56 21 12 13 13 6 5 21 147 
Variants were grouped according to amino acid similarity within the PND region 
bStage of disease 
°Days post inoculation from which variants were isolated 
dVariants that did were so dissimilar that they did not segregate into one of the defined 
groups 
"Number of variants in a group 
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Table 2. Divergence of PND Groups 
PND 
Group3 1 II III IV V 
1 0.000 0.038» ± 0.002 0.028 ± 0.005 0.299 ±0.015 0.471 ± 0.024 
II 0.000 0.044 ±0.006 0.331 ± 0.027 0.478 ± 0.040 
III 0.000 0.255 ± 0.028 0.315 ±0.034 
IV 0.000 0.697 ±0.173 
V 0.000 
1 PND groupings are as described in Table 1. 
b Between group divergence was calculated as the average number of nucleotide 
substitutions per site between groups, D%y, ± standard error. 
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Table 3. Neutralization titer of PND chimeric virus by heterologous and autologous sera 
Serum PND-I PND-III PND-IV PND-V SPEIAV-19R 
Heterologous1 16 32 16 <4 64 
Autologous2 128 64 32 4 64 
1 Wild-type EIAVMA-convalescent serum 
2Pony 524 serum (498 dpi) 
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Figure I. Clinical profile of Pony 524. Stages of disease are indicated at top of 
figure. Chronic stage is boxed. Fever episodes are indicated in columns on y-axis. 
Virus neutralizing antibody titer to EIAVwsu-s is indicated by red line. Date of 
serum samples from which viral RNA was isolated are indicated along x-axis. 
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Figure 2. Estimates of diversity, Pi and Theta, within each 
group and for outliers. Pi is the expected proportion of pairwise 
differences per nucleotide site, often referred to as nucleotide 
diversity. Theta measures the genetic variation as the expected 
proportion of segregating sites, a calculation that incorporates 
the mutation rate at each site. 
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Figure 3. Identity of the Pony 524 V2-V4 amino acid sequences in SPEIAV19R. The PND-I protein sequence is at the top of 
the alignment. Dots represent sequence identity; hyphens represent gaps. Representative variants for each of the five major 
groups were based upon V3 identity. The variable regions are boxed: variable region 2, V2; variable region 3, V3; variable 
region 4, V4. Amino acid numbering begins with the SPEIAV19R SU open reading frame for V2. 
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Figure 4. EIAV chimeric proviral clone. The long terminal repeats (LTR), gag, pol, 
envelope (SU, surface unit envelope glycoprotein, in yellow, TM, transmembrane 
protein, in dark blue), and Rev (dark blue, overlapping with TM) genes are indicated. The 
green box indicates the V2-V4 subregion of SU that contains the pony 524 wild-type 
genotypes in the infectious molecular pro viral backbone, pSPEIAV19R. 
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Figure 5. Development of virus neutralizing antibody to the chimeric viruses. Titer is on y-
axis; serum obtained at sequential days post inoculation (dpi) is indicated on x-axis. Stages of 
disease are indicated at top ban acute, yellow; chronic, light blue; inapparent, dark green; 
late febrile, red. Size of circles above graph is proportional to the percent of variants 
represented by the respective chimeric virus at stage of disease. PND-I, I; PND-II, II; PND-
m, III; PND-IV, IV; PND-V, V. Days post inoculation, DPI. The parental backbone, 
SPEIAV19R, is graphed in black. 
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Figure 6. Location of putative N-linked glycosyiation sites and 
distribution of charged amino acids of PND Groups I to V. 
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Figure 7. Comparison of chimeric virus replication in equine dermis cells (ED) and monocyte-
derived equine macrophages (MDM). Stocks of chimeric virus were assayed for RT activity and 
equivalent RT counts were inoculated in triplicate onto ED and MDM. Supematants were 
assayed for RT activity over time. 
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Figure 8. Replication of chimeric viruses and backbone, SPEIAV19R, 
in equine dermis cell cultures. Equivalent RT counts of virus stock 
were determined by RT-assay and inoculated in triplicate onto cells. 
Supematants were collected and assayed for virion RT-activity over ten 
days. 
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Figure 9. Replication of chimeric viruses and backbone, SPEIAV19R, in 
equine monocyte-derived macrophage cultures. Equivalent RT counts of 
virus stock were determined by RT-assay and inoculated in triplicate 
onto cells. Supematants were collected and assayed for virion RT-
activity over ten days. 
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CHAPTER 4. GENERAL CONCLUSION 
Most lentiviral infections are characterized as having an insidious progression. Some, 
such as HIV, SIV, and feline immunodeficiency virus (FTV), eventually result in immune 
compromise and death from opportunistic infections. In contrast, EIAV may result in a 
variable disease course with rapid onset that can progress to a stage of inapparent disease 
(15). During the inapparent stage of disease, there is ongoing virus replication (1,7), yet the 
host achieves immunologic control of the virus. Several studies have attempted to 
characterize the elements associated with immunologic control during the inapparent stage of 
disease; however, no specific correlates of protection have been identified (6-8). Efforts to 
understand the host-virus interactions that occur during the inapparent stage of disease have 
been hampered by a paucity of knowledge of the viral genotypes and phenotypes present. We 
have taken advantage of the EIAV model to study the host-pathogen interactions that occur 
during inapparent disease to gain insight into how the virus persists. In particular, we have 
characterized SU genotypes present during the acute, chronic, and inapparent stages of 
disease. We additionally performed in vitro analyses of the neutralization and replication 
phenotypes of representative SU viral variants at successive stages of disease, including the 
inapparent stage of disease. 
Variation of EIAV SU variants daring disease progression 
Lentiviruses exist in vivo as a population of closely related variants, termed a 
quasispecies. Genetic diversity within the population is due to events inherent in the 
conversion of the viral RNA genome into double-stranded DNA during reverse transcription. 
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Reverse transcription is mediated by an RNA-dependent DNA polymerase, reverse 
transcriptase (RT), which has a high error rate and lacks proof-reading capacity(4,5,10,l 1). 
Selection by host factors can influence the population of variants present To examine the SU 
viral genotypes that persist during the inapparent stage of disease, we undertook a 
longitudinal analysis of genetic variation in an experimentally infected pony. A rapid and 
significant increase in genetic heterogeneity was observed during the inapparent stage of 
disease, suggesting that diversifying selection is driving variation during this stage of disease. 
Variation was characterized by deletions/insertions in the principal neutralizing domain, as 
well as by point mutations in each SU variable region. Surprisingly, these marked genetic 
changes did not result in recrudescence of clinical disease, as might be expected if immune 
evasion were the sole selective factor, hi fact, semi-nested RT-PCR identified genotypes 
present in the inoculum that arose and became predominant late in the inapparent stage of 
disease. These data suggest that the selective environment during the inapparent stage of 
disease is distinct from that early after infection. Although it is clear that maturation of the 
immune response occurs with progression to the inapparent stage of disease, it is apparent 
that the increased diversity and divergence we observed for the inapparent stage of disease 
does not result in clinical disease. Thus, biological as well as immunological factors may 
drive quasispecies evolution during disease progression. 
Biological Characterization of Predominant V2-V4 SU Genotypes 
Despite the many different approaches used to evaluate immune function during the 
inapparent stage of disease, the specific immune responses associated with control of virus 
load remain unclear. To date, no specific correlate of immunologic control has been defined 
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(6,7). Indeed, the recent finding that there is ongoing virus replication during the inapparent 
stage of disease, often at levels attained during clinical disease, suggests that there is a set 
point of virus load at which the horse can maintain immunologic control. In order to better 
understand the phenotypic differences that characterize variants predominant at the acute, 
chronic ,  and  inapparen t  s tages  o f  d isease ,  ch imer ic  v i ruses  conta in ing  the  predominant  VI­
VA SU variants were assessed for in vitro neutralization and replication phenotypes (Chapter 
3). 
An important discovery was that VNAb also contributes to control of initial viremia. 
This finding contradicts previous assertions that neutralizing antibody does not contribute to 
resolution of acute disease (12). It is unclear why previous studies did not also detect the 
presence of neutralizing antibody early in the course of disease. One possible explanation 
may be that the inoculum used for experimental infection can influence the neutralization 
phenotype of variants that arise early in disease. The inoculum used to infect pony 524 was 
passaged in vivo with virus collected during acute disease (13). It is possible that this method 
of in vivo propagation selected for variants susceptible to neutralization since the viral 
quasispecies did not encounter a mature immune response during passage. In contrast, 
EIAVpy, a biological clone used by some investigators for studies characterizing the immune 
responses of EIAV infected horses (6-8), might be expected to have a neutralization resistant 
phenotype. Indeed, EIAVpy is a neutralization escape mutant derived by thirteen passages of 
virus in cell culture in the presence of a broadly neutralizing serum obtained from an 
experimentally infected pony at 203 dpi (14). The development of the humoral immune 
response of horses infected with other wild-type isolates also suggests that there may be wide 
variation in the development of neutralizing antibody (3). Future studies characterizing the 
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development of neutralizing antibody in horses infected with different inoculums may 
provide a greater perspective in understanding the contribution of neutralizing antibody in the 
resolution of acute disease. 
The significance of the type-specific neutralizing antibody response observed with 
resolution of acute disease is incompletely understood. In HIV and EIAV, cell-adapted 
strains tend to replicate better than wild-type strains and also tend to be more sensitive to 
neutralization (2,3,10). Thus, the absence of selective pressure by a mature humoral immune 
response can result in neutralization sensitive virus with a capacity for high replication. 
These findings suggest that the EIAVWyo inoculum used to infect pony 524 may have 
undergone selection for high-replicating, neutralization sensitive virus during passage, and 
that type-specific responses are directed toward a less robust neutralization phenotype. 
Regardless of whether or not the inoculum contributes to determination of the initial 
specificity of the humoral response, we observed a rapid selection of variants resistant to 
type-specific antibody that were neutralized later. 
The observation that SPEIAV19R, PND-II, and -HI, were neutralized at the same 
time and to similar titer suggests that these viruses were neutralized by broadly reacting, 
cross neutralizing antibody. Further, these results suggest that these viruses contain common 
epitopes. The observation that differences in genotype restricted to V2-V4 can impact 
neutralization phenotype indicates that a molecular-based approach of defining common 
epitopes may be possible. 
Our results also indicated that variants acquire increasing resistance to neutralizing 
antibody as disease progresses and extend the findings of Howe et al. who detected increased 
resistance to neutralization by V3-V4 variants with disease progression (9). We demonstrated 
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that variants present during the inapparent stage of disease become predominant in the face 
of broadly reactive, cross neutralizing antibody. This suggests that there is selection of 
variants resistant to neutralization during inapparent disease. Thus, in general, persistent 
virus appears to have a resistant neutralization phenotype. This generalization does not 
exclude the possibility that other viral phenotypes promote resistance. 
Interestingly, the viral genotype with the greatest resistance to VNAb showed reduced 
replication in ED and MDM. Considered together, the trade-off of decreased replication 
capacity for increased resistance to neutralization appears to be favorable for variants that 
persist during EIAV infection. In the present case, an episode of viremia, fever, and 
thrombocytopenia accompanied the predominance of this genotype, suggesting that persistent 
variants do not necessarily lose the capacity for inducing clinical disease. Since other viral 
genes have been demonstrated to impact the disease course in EIAV infected equids (1), the 
relative role SU variation played in this episode of disease is unclear. 
Future Studies 
The phenotypic characterization of EIAV SU variants in the context of an infectious 
clone performed in these studies validates this approach for studying differences in viral 
phenotype. However, the results also indicate a need for other studies to extend and clarify 
our current understanding of viral variation with regard to persistence. Inclusion of other 
predominant genotypes with a capacity for influencing phenotype should be considered. For 
example, V5 also contains a linear epitope for neutralizing antibody, suggesting that other 
domains of SU should be examined in the context of an infectious clone. Also, the 
interfebrile periods present during the clinical stages of disease have not been investigated. 
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Studying the interfebile periods may provide insight into virus-host interactions that favor 
onset of disease episodes. An understanding of what portends clinical disease would also 
better clarify factors that enhance persistence. 
To better define the mechanisms that are important in EIAV for escape and 
persistence of virus, site directed mutagenesis studies may be performed. For example, only 
four amino acids differed between PND-I and PND-H, yet their neutralization phenotypes 
differed considerably. It was suggested in Chapter 3 that the gain of a putative N-glycan 
accounted for the difference in neutralization phenotype. Site directed mutagenesis would be 
able to test this hypothesis. The results would extend our understanding of genetic 
differences that account for the phenotypic differences, and would, by extension, help to 
understand the dynamics of the quasispecies. These studies could be expanded to include a 
broader analysis of the differences in amino acid charge and N-linked glycosyiation 
identified between all of the chimeric viruses. 
Several of the chimeric viruses were neutralized at the same time and to the same 
titer, suggesting that they were neutralized by antibody that recognized a conserved epitope 
that they shared. These results indicate that a molecular based approach may facilitate 
identification of epitopes for broadly acting, cross neutralizing antibody. These epitopes 
would be potential candidates for inclusion in vaccine development studies, as they appear 
important in maintenance of immunologic control of EIAV. 
The present studies represent quasispecies evolution in a single, experimentally 
infected animal. A more complete understanding of viral variation and persistence will be 
. gained by undertaking similar studies using other experimentally infected equids. During 
disease progression, variation occurs in other regions of the EIAV genome, including Rev 
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(I). It will be of tremendous interest to characterize these phenotypes individually through 
similar molecular techniques, and then together with genotypes from other regions of the 
genome, e.g. SU and Rev. Ultimately, once a broader perspective is gained, such studies 
should progress in due course to include in vivo infection studies. 
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APPENDIX. METHODS FOR CONSTRUCTION OF CHIMERIC VIRUS AND 
GENERATION OF VIRUS STOCKS 
RT-PCR amplification and cloning 
A 440 nucleotide region of the env gene was amplified from viral RNA using primers 
designed based on conserved regions of the envelope as determined from EIAV env 
sequences available GenBank data. The following primers were used for RT-PCR 
amplification: CG5673 and CG6112C\ To obtain viral RNA, 200 fj.1 of serum from the 
experimentally infected pony was centrifuged at 93,000 x g for one hour at 4° C. Viral RNA 
was isolated from the pellet by guanidine thiocyanate lysis and acid phenol-chloroform 
extraction using a commercially available kit (Ambion, Austin, TX). The RNA was then 
resuspended in 25 pi RNase-free glass distilled water containing 0.1 mM EOT A. Samples 
were DNase treated by adding two units of DNase I (Ambion, Austin, TX) added to 3 |il of 
viral RNA, 20 mM MgClz, 1 mM of each dNTP, IX PCR buffer n (Perkin-Elmer, 
Branchburg, NJ), 20 units of RNase inhibitor, and 2.5 mM of random hexamers in a total 
volume of 20 gl. The reaction was incubated at 37° C for 30 minutes and heated to 75° C for 
5 minutes to inactivate the DNase. After cooling to 4e C, 50 units of Maloney murine 
leukemia virus reverse transcriptase was added. Reactions were incubated at 42° C for 45 
minutes, heated to 99° C for 5 minutes, and then cooled to 5° C for 5 minutes. Reactions 
were then brought up to 100 pi with 2 mM MgClz, 0.2 mM of each dNTP, IX PCR buffer H, 
2.5 units of Taq polymerase, and 1 pM of each primer. PCR amplification conditions were 
37 cycles of denaturation at 94e C for two minutes, annealing at 50e C for 1 minute, and 
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extension at 72° C for I minute. The initial and final cycles contained a prolonged extension 
at 72° C for 5 minutes. 2 gl of PCR product were TA-cloned into pGEM-T vectors according 
to the manufacturer's recommendations and transformed into Escherichia coli DH-5a. 
Positive clones were identified by colony blot hybridization using a subgenomic fragment of 
env labeled with [32P]dTTP by random primed labeling (Roche Molecular Biochemical, 
Indianapolis, IN). Plasmids were isolated from positive clones and the env inserts were 
sequenced bidirectionally with primers to vector sequences flanking the insert. All 
sequencing was performed by the Iowa State University DNA Synthesis and Sequencing 
Facility using an automated DNA sequencer. Sequences were aligned by MacVector and 
AssemblyLIGN software (Oxford Molecular, Beaverton, OR). 
Choosing the representative wild-type genotypes. 
Selection of representative motifs for construction of chimeric viruses was based 
upon alignment of V3; five major groups segregated according to predominant V3 motif. 
The genotype which best represented each of the groups was used in construction of the 
chimeric virus. From our previous data set (2), 126 clones segregated into five major and two 
minor groups. To assure distinct grouping of amino acid variants, measures of genetic 
diversity and divergence were calculated. The genetic diversity of each of these groups was 
estimated in terms of per-nucleotide expected heterozygosity, or nucleotide diversity within 
the V3 subregion of V2-V4. Two estimates of nucleotide diversity were calculated using 
DnaSP version 3.51,8 and it. Between group divergence was then measured as the average 
number of nucleotide substitutions per site between groups, Dxy. 
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Construction of chimeric viruses: V2-V4 (Bsu36I - Sphl) 
The overall strategy for construction of chimeric infectious clones containing variant 
env was to generate env subclones which could be more easily manipulated for insertion of 
the variant sequences and reconstitution of the full length viral genome. To generate the first 
subclone, pSPEIAV19R was digested with the pair of unique restriction enzymes 
SphVEcoRL, resulting in an insert fragment -1.8 Kb after deletion between two HindHI sites. 
This SphUEcoR lAHindlU fragment was purified and ligated into the low copy vector 
pLG338/30, which had been digested with SphVEcoRL Plasmids containing the 
predominant env variants were digested with Sph IIBsu 361, and the insert fragment 
containing the variant sequences was purified and inserted into PND-I-LG338/30 similarly 
digested with Sph IIBsu 361. Thereafter, PND-I-LG338/30 was digested with Sphl/Nhel, and 
this fragment was purified and ligated into a similarly digested PND-II-pUC, which contains 
the Sphl/EcoRI fragment of pSPEIAV19R in pUC. PND-II-pUC was digested with 
Sphl/EcoRI and this fragment was Ligated into PND-m-ASpA//flsu36I, which generated the 
full length clone. Plasmids containing chimeric env were verified by nucleotide sequencing 
at the PND-I-LG338/30 and PND-HI-ASp/r//Zfau361 stages of cloning. 
Cell lines 
Equine dermis cells (ED, ATCC CCL 57) and canine fibroblast cells (Cf2th, ATCC 
CRL 1430) were maintained in Dulbecco's modified Eagles medium (DMEM) supplemented 
with antibiotics and fetal calf serum. Monocyte derived macrophage cultures (MDMCT) were 
established as we previously described {9354,(3). Briefly, whole blood was obtained from 
EIAV-free horses by jugular venipuncture. Mononuclear leukocytes were banded by 
centrifugation at 750 x g on a discontinuous histopaque gradient, resuspended in Dulbecco's 
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MEM (DMEM) containing 20% horse serum and 10% newborn calf serum (NCS), and 
seeded at 2 x 107 cells/cm2 in 24 well tissue culture plates. Monocytes were allowed to 
adhere overnight at 37°C and nonadherent cells were removed from the cultures by washing 
twice with Hank's buffered saline solution (HBSS) containing 2% fetal calf serum (PCS). 
Cells were maintained in DMEM containing 20% horse serum, 10% NCS and antibiotics. 
Characterization of vires replication 
Stocks of chimeric virus were assayed for RT activity and equivalent RT counts were 
inoculated in triplicate onto ED and MDM. The cells were washed and media replaced the 
day after inoculation. Supernatant was collected following the media change and every two 
days for a two week period. Supematants were assayed for virus RT-activity, expressed as 
cpm/gl supernatant (1). 
Virus Neutralization Assay 
Virus neutralization assays were performed using equine dermal cells (ED) 
maintained in Dulbecco's modified eagle medium (DMEM) supplemented with fetal calf 
serum, penicillin, and streptomycin as previously described (1). Neutralizing antibody titers 
were assayed in sera samples from at least two different time points from each of the clinical 
stages of disease, and pre-inoculation serum was used as a negative control. Sera was heat 
inactivated to destroy complement, serially diluted two-fold in supplemented DMEM, and 
incubated at 37°C for 1 hr with 500 focus forming units (FPU) of the cell adapted EIAVWsu-s 
. Quadruplicate wells of ED cells were inoculated with the virus-serum mixture in the 
presence of 4 gg polybrene, and the culture media was changed the following day. Cells were 
incubated for an additional 72 hours, fixed with ice cold methanol, and foci of EIAV-infected 
cells were detected by immunocytochemistry. Foci of infected cells were counted and results 
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were expressed as the serum neutralization titer, defined as the highest serum dilution that 
gives a 75% reduction in foci as compared with preimmune and negative control serum. 
Construction of chimeric viruses: V2-V4 (Bsu36I-SphI) chimeric backbone with V5-V7 
Use PND-HI-LG338/30 plasmid with desired V2-V4 as template and amplify using 
primer pair CL5995 and CL6435C-H31. Digest the PCR product with Xbal and gel purify 
DNA. Amplify the V5-V7 from the appropriate pGem-T-EZ plasmid using CL5995 and 
CL6435C'. Digest the product with Xbal and gel purify the DNA. Ligate the two gel purified 
products. Make serial dilutions of the ligation product to 10"3 and use it as a template for PCR 
using CL5995 and CL6435C-H322 as primers. Use Hindm to digest the PCR product Gel 
purify the latter and ligate the DNA into 74-91 A# 10, transform, and screen transformants for 
the correct orientation. Digest the appropriate clone with Sphi/EcoRI and ligate into 
pSPEIAV19R Sphl/EcoRI fragment (PND-HI-LG338/30) and screen for the correct clone. 
Primer Name Nucleotide Sequence 
CG5673 AATGCTGGGGTTCCTTCC 
CG6112C* ACACAGCCTGATTGGATG 
CL6435C--H31 TTAAAGCTTTGGTTCCTTAl ICI IL lUl'lAGGTCTATTCAGTTCTAAGTGTGCCTGTCCTATAACTCC 
CL6435C'-H32 
CL5995 CCTAAGGGGTGTAATGAG 
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